Link.preclinical,ID.preclinical,doc_name.preclinical,has_clinical.preclinical,Year.preclinical,acute.sustained.preclinical,sample.group.size.preclinical,outcome.count.preclinical,disease.preclinical,outcome.direction.preclinical,gnotobiotic.preclinical,animal.strain.preclinical,animal.sex.preclinical,animal.age.value..days..preclinical,animal.age.description.preclinical,animal.weight.value..g..preclinical,animal.weight.description.preclinical,species.preclinical,mechanism_of_action.preclinical,disease.model.preclinical,intervention.delivery.preclinical,success.measure.preclinical,tested.dose.dependently.preclinical,prophylactic...therapeutic.preclinical,ribotype.preclinical,c.diff.strain.preclinical,c.diff.dose.value.preclinical,c.diff.dose.units.preclinical,c.diff.dose.vegetative.spores.preclinical,c.diff.dose.description.preclinical,daily.dosage.preclinical,total.dosage.preclinical,dosage.value.preclinical,dosage.units.preclinical,dosage.times.per.day.preclinical,dosage.duration.preclinical,dosage.description.preclinical,intervention.preclinical,comparator.preclinical,accute.efficacy.preclinical,sustained.efficacy.preclinical,comment.preclinical,Done..preclinical,matched.preclinical,case.ID.clinical,acute.sustained.clinical,daily.dosage.clinical,total.dosage.clinical,dosage.value.clinical,dosage.units.clinical,dosage.times.per.day.clinical,dosage.duration.clinical,dosage.comment.clinical,intervention.class.clinical,intervention.clinical,dose.dependence.clinical,sample.group.size.clinical,prophylactic...therapeutic.clinical,outcome.clinical,outcome.direction.clinical,measure.description.clinical,author.conclusion.clinical,conclusion.method.clinical,References.clinical,NCT.Number.clinical,Title.clinical,Gender.clinical,Age.Groups.clinical,Age.Description.clinical,Phases.clinical,URL.clinical,outcome.count.clinical,intervention.match.type.clinical,el.p.value,er.p.value,translation
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,1,2.53987906196E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,1,2.36678962502E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,1,6.94771900591E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,1,6.82305622098E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,1,1.0738848766E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,1,2.56362688647E-10,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.0420489538568,0.37577944379,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.999650672239,1.10139490351E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.979662418183,0.000290299838438,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.956169714239,0.000889461588392,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.94915183992,0.000513546182484,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.784084037937,0.0119272983814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.999922047792,0.000851437231983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.107360761382,0.123750950774,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.00309415504863,0.0384260307241,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.00333730695128,0.0272931235544,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.00149721435799,0.280552304455,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.00256229336771,0.0862370257309,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.00187078097006,0.257003658752,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.00319411291237,0.0278691206268,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,4.29390875565E-11,0.999999999202,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00159053312238,0.33199923081,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,6.28279207681E-05,0.95634548741,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,1.6921139534E-05,0.999987781526,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,6.04276907571E-05,0.949156392521,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.000174499471832,0.91434506062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0224037346217,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.40586533663E-12,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.158478605027,0.0494611020975,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.136712723458,0.05701750999,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.110281526034,0.409579520384,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.12379123586,0.126060909151,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.115244568283,0.409579520384,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.15106245548,0.0522675524174,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.000191132680915,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.119040301803,0.409579520384,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0478610112819,0.956338745302,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0448775755617,0.999987779571,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0499388552426,0.949148811642,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.0402351372821,0.914348472953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.409579520794,0.327659520758,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23689716,23689716,23689716.txt,True,2013,acute,4,4,C. difficile disease,positive,axenic,,,5,5 days,,,pig,,challenge,,cumulative mortality,True,therapeutic,27,UK6,1000000,,spores,10^6,40,280,20,mg/kg,BID,7,,vancomycin,Negative Control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000468766835344,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,1,5.98588324152E-14,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,1,1.25561373185E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,1,5.38663658848E-13,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,1,1.48212464847E-15,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,1,3.12615139193E-14,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,1,3.84656946679E-15,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.598114315287,0.0175386619096,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.999999999998,3.82190226631E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,1,4.12673246812E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,1,3.35010379254E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.999999999905,7.78529653771E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.999686070266,3.2269087459E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,1,2.51090880984E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,1,5.98588324152E-14,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,1,1.25561373185E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,1,5.38663658848E-13,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,1,1.48212464847E-15,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,1,3.12615139193E-14,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,1,3.84656946679E-15,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.598114315287,0.0175386619096,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.999999999998,3.82190226631E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,1,4.12673246812E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,1,3.35010379254E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.999999999905,7.78529653771E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.999686070266,3.2269087459E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,1,2.51090880984E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.996512619571,6.16424101514E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.999910040117,3.14104239741E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.974465134821,2.28916718283E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.998443754056,5.25207050827E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.989185621951,4.55057763219E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.999204109043,9.37825949262E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.00431137105999,0.798232935522,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.879108503697,0.000448280813167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.677769327222,0.00618206771219,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.393034188551,0.0175603829462,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.515680514903,0.00988190754563,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.494577067409,0.0664384297618,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.993629280575,0.00852995272442,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00524762986259,0.557732354609,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.107360761382,0.00586377217672,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0752282699896,0.0015239120492,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0538222394142,0.0285996428781,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0681481354154,0.00584973912485,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0618231411338,0.0199879828195,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.107360761382,0.00291456384222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,2.49260393718E-06,0.999996697153,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.107360761383,0.107360761383,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0176453014005,0.515341778343,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00914569627625,0.794948825471,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.013931780918,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.0172490829377,0.73818869616,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.37579453956,0.114150415211,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,acute,10,9,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,3.05510449394E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,acute,10,10,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,10,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,vancomycin,control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.077354625785,0.0525754451227,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0777751326113,0.0483237526807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0544527991596,0.332161708823,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.066472320727,0.110461943543,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0610274892352,0.305280279183,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.072108041892,0.0386623903624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.38497692541E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0685499040197,0.332023262504,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.024217776199,0.956339618497,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0163901480338,0.999987779815,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0193783722707,0.949149827952,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.018809496924,0.914350014509,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.262124340208,0.327659521126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,6,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.53023962064E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,10,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0080153174566,0.037342915377,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0080168677216,0.0301829368069,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.00470773202312,0.351806778452,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.00624318208024,0.0843684241256,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.00529097373833,0.286771451327,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.00786379142359,0.0294295129067,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,9.12191494443E-10,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00560884913622,0.351806784141,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.000379866959732,0.956343789822,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00010710762904,0.999987781037,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.000298131240982,0.949154469674,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.000453125300241,0.914345060157,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0368590317245,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,16,16,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,3.85192425214E-10,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.167755383518,0.00416128498923,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.167755383518,0.00100658053516,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.112308692853,0.0224846515884,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.167755383518,0.00451961907515,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.116107796099,0.0151379497437,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.167755383518,0.00202253470571,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.88620561594E-05,0.999967371989,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.167755383519,0.0764978732703,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0384153309701,0.503287120239,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0228523716276,0.723205154907,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0359853699628,0.503287120241,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.0384743682447,0.577508769018,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.503301800523,0.0977102448629,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,8,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.85362872983E-05,0.999999999965,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.999999999996,5.75085165198E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,1,5.14335996269E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,1,2.06075758185E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,1,8.40134733632E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,1,6.01018503755E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,1,9.28353839778E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.0442842406627,0.453214918754,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.999650658389,0.00021026968444,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.956339618497,0.00335966636658,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.852572791894,0.0100857898081,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.893191580214,0.00557173579112,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.738185613821,0.0280221559027,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.998399692781,0.00238981325221,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0915506807532,0.262124339814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.077354625785,0.0525754451227,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0777751326113,0.0483237526807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0544527991596,0.332161708823,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.066472320727,0.110461943543,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0610274892352,0.305280279183,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.072108041892,0.0386623903624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.38497692541E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0685499040197,0.332023262504,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.024217776199,0.956339618497,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0163901480338,0.999987779815,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0193783722707,0.949149827952,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.018809496924,0.914350014509,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.262124340208,0.327659521126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.53023962064E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.077354625785,0.0525754451227,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0777751326113,0.0483237526807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0544527991596,0.332161708823,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.066472320727,0.110461943543,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0610274892352,0.305280279183,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.072108041892,0.0386623903624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.38497692541E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0685499040197,0.332023262504,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.024217776199,0.956339618497,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0163901480338,0.999987779815,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0193783722707,0.949149827952,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.018809496924,0.914350014509,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.262124340208,0.327659521126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,6,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.53023962064E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.077354625785,0.0525754451227,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0777751326113,0.0483237526807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0544527991596,0.332161708823,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.066472320727,0.110461943543,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0610274892352,0.305280279183,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.072108041892,0.0386623903624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.38497692541E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0685499040197,0.332023262504,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.024217776199,0.956339618497,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0163901480338,0.999987779815,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0193783722707,0.949149827952,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.018809496924,0.914350014509,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.262124340208,0.327659521126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,acute,6,6,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.53023962064E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.00365446034398,0.0380450677631,equivalent
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.00391879592152,0.0262375742082,equivalent
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.00180163180833,0.272634222731,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.00325511374471,0.0862689518953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0024125485062,0.243723062259,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.00418323195339,0.0281855262976,equivalent
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,8.8617937668E-11,0.999999996599,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00234953258168,0.331999230409,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,8.97341498778E-05,0.956345063019,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,2.65897354334E-05,0.999987781404,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,8.24303685784E-05,0.949155911816,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00019569104004,0.914345060494,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.018601688606,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,acute,19,19,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,1.36429934548E-11,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.76513716556,0.000117937999861,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.737259519872,9.91695414236E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.737259519872,0.000675662955135,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.737259519872,6.66446076298E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.737259519872,0.000327153379207,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.761051230906,5.06186788646E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.00570482900553,0.918299674074,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.737259519872,0.00923193919412,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.41645065776,0.0672945709058,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.327659520512,0.162633554247,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.411705668471,0.0842770286946,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.436192517201,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.942074879987,0.022561659055,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29109161,29109161,29109161.txt,True,2017,acute,5,3,Clostridium difficile infection,positive,,C57BL/6,F,56,8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,20,mg/kg,QD,5,,vancomycin,pbs control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0115604332129,0.768930533284,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,1,1.03977854019E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,1,5.06310611344E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,1,1.77194697761E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,1,5.42246921748E-15,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,1,1.06426607937E-13,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,1,2.29735955572E-14,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.322093023766,0.0438785059018,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.999999999171,2.72864309175E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.999999997559,1.19906398643E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,1,8.64937663025E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.999999610268,3.77011034419E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.988343915558,0.000234238892941,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.99999997951,1.44380875946E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.617368329912,0.0109153654356,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0630416674213,0.00194386927234,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0399234767593,0.000206469989112,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0254857280042,0.0104177776479,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0325625513084,0.00131507666949,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0286994240543,0.00539127939497,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0518532789281,0.000843101551606,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.52049640458E-07,0.999967374365,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0479508841107,0.0644342598135,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00371005374479,0.548834335448,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00113249439617,0.758189198774,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00373184226254,0.548834346496,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00849913789189,0.584318858646,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.327659520512,0.0915022749433,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,17,15,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,8.86628527241E-09,0.999999999965,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0244181292062,0.0435431593396,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0231140258389,0.0346523475912,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0156881554255,0.322093020223,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0197271718234,0.0889448787679,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0175568709803,0.322093020223,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0237882169299,0.0335323936563,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,5.13655917604E-08,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0154875778509,0.332022419305,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00246811667242,0.956341788223,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00130576432196,0.999987780426,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00246822690659,0.949152278756,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00189762530509,0.914352326723,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0858993458314,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,11,11,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,7.86007642996E-08,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.00138147943751,0.0389418024377,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0012825711031,0.0258950419254,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.000506471290991,0.272639415786,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.000866579738561,0.0851620475192,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.000671677706293,0.26382302617,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.00116153057133,0.0290456655497,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,5.62152746522E-12,0.999999999998,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00056786099653,0.331999232623,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,1.32743018851E-05,0.956346662749,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,2.40641805767E-06,0.999987782014,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,9.58708617505E-06,0.949157015843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,4.45550837296E-05,0.914345061188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0158830521176,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,6.75872054659E-14,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.00138147943751,0.0389418024377,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0012825711031,0.0258950419254,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.000506471290991,0.272639415786,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.000866579738561,0.0851620475192,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.000671677706293,0.26382302617,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.00116153057133,0.0290456655497,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,5.62152746522E-12,0.999999999998,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00056786099653,0.331999232623,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,1.32743018851E-05,0.956346662749,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,2.40641805767E-06,0.999987782014,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,9.58708617505E-06,0.949157015843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,4.45550837296E-05,0.914345061188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0158830521176,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,24,24,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,6.75872054659E-14,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0080153174566,0.037342915377,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0080168677216,0.0301829368069,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.00470773202312,0.351806778452,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.00624318208024,0.0843684241256,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.00529097373833,0.286771451327,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.00786379142359,0.0294295129067,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,9.12191494443E-10,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00560884913622,0.351806784141,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.000379866959732,0.956343789822,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00010710762904,0.999987781037,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.000298131240982,0.949154469674,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.000453125300241,0.914345060157,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0368590317245,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,3.85192425214E-10,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.10465891078,0.0503454091111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0947398842393,0.0513114856065,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0734041989807,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0862506624606,0.117520545412,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.079597948409,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0976022758972,0.0430751863043,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,5.75560374261E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0777173451916,0.332019256606,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0380966231304,0.95633918191,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0252508094327,0.999987779693,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0247214883216,0.949149320043,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.0345473042508,0.914349188672,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.327659520922,0.327659520922,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,vehicle control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000152128815653,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,acute,10,10,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.077354625785,0.0525754451227,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0777751326113,0.0483237526807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0544527991596,0.332161708823,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.066472320727,0.110461943543,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0610274892352,0.305280279183,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.072108041892,0.0386623903624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.38497692541E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0685499040197,0.332023262504,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.024217776199,0.956339618497,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0163901480338,0.999987779815,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0193783722707,0.949149827952,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.018809496924,0.914350014509,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.262124340208,0.327659521126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.53023962064E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.033520365257,0.0438816930015,equivalent
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0294806110584,0.0366248680375,equivalent
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0196944661953,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0270208828696,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0242274454796,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0325290639922,0.0334997892209,equivalent
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.37214454519E-07,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0232279311809,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0041356088598,0.956341352843,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00222545089687,0.999987780304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00338337618805,0.94915183992,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00326189439488,0.914351666079,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.10737418235,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0118195965145,0.0396838657132,equivalent
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0114148524312,0.0317508431097,equivalent
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.00783516450724,0.301416771682,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.00970522364926,0.0855383477428,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0084022875435,0.268230276641,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0120203008771,0.0319370386512,equivalent
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,3.49619743714E-09,0.999999986984,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00884327010604,0.332028743547,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.000795031590472,0.956343055249,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.000315625524713,0.999987780793,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.000708171451356,0.949153778982,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.000740867304146,0.914354308475,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0439804649667,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,acute,14,14,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.95751981583E-09,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.76513716556,0.000117937999861,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.737259519872,9.91695414236E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.737259519872,0.000675662955135,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.737259519872,6.66446076298E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.737259519872,0.000327153379207,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.761051230906,5.06186788646E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.00570482900553,0.918299674074,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.737259519872,0.00923193919412,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.41645065776,0.0672945709058,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.327659520512,0.162633554247,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.411705668471,0.0842770286946,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.436192517201,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.942074879987,0.022561659055,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0115604332129,0.768930533284,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.10465891078,0.0503454091111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0947398842393,0.0513114856065,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0734041989807,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0862506624606,0.117520545412,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.079597948409,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0976022758972,0.0430751863043,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,5.75560374261E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0777173451916,0.332019256606,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0380966231304,0.95633918191,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0252508094327,0.999987779693,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0247214883216,0.949149320043,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.0345473042508,0.914349188672,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.327659520922,0.327659520922,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000152128815653,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.0479963533317,0.0479944896981,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0438629613491,0.0375388713844,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0337487012887,0.337782660634,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.0438985265154,0.10902156625,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0399534330623,0.308728146017,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.0498878287446,0.0373902091306,equivalent
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.16840020688E-06,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0335547268928,0.332016094156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.00791378520813,0.956340491046,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.00611747792212,0.99998778006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.00739860165429,0.949150841268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.00833506365105,0.914350344783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.167755383854,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.077354625785,0.0525754451227,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.0777751326113,0.0483237526807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.0544527991596,0.332161708823,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.066472320727,0.110461943543,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.0610274892352,0.305280279183,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.072108041892,0.0386623903624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,1.38497692541E-05,0.999999986983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.0685499040197,0.332023262504,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.024217776199,0.956339618497,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0163901480338,0.999987779815,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.0193783722707,0.949149827952,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.018809496924,0.914350014509,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.262124340208,0.327659521126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,10000000,CFU,spores,10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.53023962064E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.297099362927,0.00302533247021,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.262124339814,0.000800717920095,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.262124339814,0.0159607587163,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.262124339814,0.00308959467756,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.262124339814,0.010429965055,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.280333793953,0.00164677949681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,0.00018977446404,0.999967371336,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.262124339815,0.0685498936526,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,0.0788609968998,0.370596239089,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,0.0564847510863,0.655335424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,0.084268894711,0.385638241436,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.0954393530594,0.655335424885,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.655347712451,0.0874418714062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000357148140694,0.999999996787,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01085591-6,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,59,intervention:Specific,0.00309415504863,0.0384260307241,equivalent
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01987895-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,270,intervention:Specific,0.00333730695128,0.0272931235544,equivalent
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02254967-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,147,intervention:Specific,0.00149721435799,0.280552304455,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01597505-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,234,intervention:Specific,0.00256229336771,0.0862370257309,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01598311-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,239,intervention:Specific,0.00187078097006,0.257003658752,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02179658-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,95,intervention:Specific,0.00319411291237,0.0278691206268,equivalent
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02743234-5,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,3,intervention:Specific,4.29390875565E-11,0.999999999202,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01222702-10,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,19,intervention:Specific,0.00159053312238,0.33199923081,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02218372-2,acute,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,44,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,31,intervention:Specific,6.28279207681E-05,0.95634548741,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT00269399-2,acute,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,115,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,73,intervention:Specific,1.6921139534E-05,0.999987781526,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02092935-2,acute,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,33,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,23,intervention:Specific,6.04276907571E-05,0.949156392521,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01818141-2,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,9,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,6,intervention:Specific,0.000174499471832,0.91434506062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01818141-4,acute,500,5000,125,mg,QID,10,125 mg QID for 10 days,antibiotic,vancomycin,no,5,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,5,intervention:Specific,0.0224037346217,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,acute,20,20,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.40586533663E-12,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.991275056676,0.00144552244924,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.999996775008,0.00212140862541,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.993296915633,0.00396667661682,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.999921717457,0.00274875582555,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.999084257311,0.00471832128714,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.999830205499,0.000759741268632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.252909853113,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.796895742882,0.0123584761525,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.998655717315,0.00022082004445,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,4.08557388398E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.840148719434,0.00377113542152,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.25040853066E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,4.26355770807E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.167755383518,0.175580444246,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,504,18 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,old control,superior,,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.167755383518,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.00557316473104,0.998407618811,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.00750151753818,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.00421059735516,0.99999999994,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.00665951432335,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.0058461046091,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.00757258975436,0.999830205499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,2.42390837867E-05,0.999996697087,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.00163766202035,0.998409242791,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.0108342163593,0.849215201067,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.0389854387036,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.00277132706698,0.991056699749,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0242730474991,0.996907060649,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0221494856745,0.99988820754,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,5.31689440862E-06,0.999999944544,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26917573,26917573,26917573.txt,True,2016,sustained,8,8,Clostridium difficile infection,positive,,C57BL/6,M,56,2 months,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,young control,superior,,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.02341367356E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,2.934718534E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,1.02496565549E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,1.95630837358E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,1.5920781881E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,3.4140835217E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.13100594665E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918303070876,0.00311452342953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517694,9.23844316317E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.8138267133E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.06753907807E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996928035,1.83136331463E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.70987242554E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.46940498032E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836923035894,0.00735075276842,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.883587017638,0.000957305725776,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.992739494893,0.00152391205062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.856116800311,0.00281256541261,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.975923123901,0.00201607605503,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.906724096182,0.00313557661711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.980775883689,0.000458605144594,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.1807332561,0.163639101766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.677769331873,0.0137129397742,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.987278522572,0.000180339814619,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999999998,1.69382172968E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.735136184029,0.00522902144858,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,3.94292867925E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.81239989383E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.107360761382,0.236878431711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.107360761382,0.123750950774,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.677769327222,0.00545137302583,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.677769327222,0.00651951336706,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.583907197791,0.00980740192282,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.677769327222,0.00758886616443,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.597720223935,0.0121126391105,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.682844669796,0.00230031402521,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.107360761382,0.37577944379,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.441080771744,0.0446187225828,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.879108501663,0.00107252006303,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999996665296,2.63787573829E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.677769327223,0.0194497343853,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.999826094011,3.90811691693E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.997043861018,0.00015113394917,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.034318683874,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.021223414827,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.207486596615,0.0579385659648,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.179812467696,0.0657520347227,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.117212236282,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.156626752796,0.0787034863319,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.113695409355,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.257761685062,0.0411687302121,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.00889289444221,0.705596097553,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.107360761383,0.249002405727,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.402945463062,0.0201443099941,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.677769327222,3.31342086613E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.193698086858,0.1458343905,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.455147126217,0.00245656686516,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.399518179011,0.00564076854461,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.00280527664237,0.8369230359,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00112444134758,0.768942047761,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0270954659402,0.416667807753,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0278364462224,0.538870611408,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0166439975633,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0224388987977,0.579333343108,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.0199879828215,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0332547770997,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.000405635252092,0.973338430559,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.0110804240555,0.732619180953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.107360761382,0.161215170874,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.226183959496,0.00265808865492,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.0235639641263,0.50069926297,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0839486723689,0.0682018094583,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0688939947304,0.109770899508,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,9.81217296062E-05,0.993340720522,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.51347518904E-05,0.9999993556,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0270954659402,0.416667807753,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0278364462224,0.538870611408,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0166439975633,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0224388987977,0.579333343108,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.0199879828215,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0332547770997,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.000405635252092,0.973338430559,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.0110804240555,0.732619180953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.107360761382,0.161215170874,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.226183959496,0.00265808865492,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.0235639641263,0.50069926297,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0839486723689,0.0682018094583,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0688939947304,0.109770899508,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,9.81217296062E-05,0.993340720522,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.51347518904E-05,0.9999993556,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1.67620362682E-05,0.998407808458,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,2.83976479756E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,6.62510928792E-06,0.99999999994,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1.99902349295E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1.08081198831E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,2.78936842603E-05,0.999830225869,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,5.03723965866E-09,0.999999819627,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,2.15327189848E-06,0.998409421517,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.000130666201944,0.849226858652,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.00199164645015,0.11196768803,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,6.20333162061E-06,0.991057655056,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.000553562469721,0.996907431781,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.000424975501755,0.999888220954,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,2.01181343581E-10,0.99999994455,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.40586533663E-12,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,2.934718534E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,1.02496565549E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,1.95630837358E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,1.5920781881E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,3.4140835217E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.13100594665E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918303070876,0.00311452342953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517694,9.23844316317E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.8138267133E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.06753907807E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996928035,1.83136331463E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.70987242554E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.46940498032E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836923035894,0.00735075276842,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,2.934718534E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,1.02496565549E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,1.95630837358E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,1.5920781881E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,3.4140835217E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.13100594665E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918303070876,0.00311452342953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517694,9.23844316317E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.8138267133E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.06753907807E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996928035,1.83136331463E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.70987242554E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.46940498032E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836923035894,0.00735075276842,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.416667807762,0.0176976020461,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.391783364612,0.0233237482565,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.375779440166,0.0364213414156,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.375779440166,0.0270208828691,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.375779440166,0.0386959362136,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.469329776711,0.0113699457529,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.0267876569016,0.598114315287,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.231892013409,0.116447063321,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.677769327223,0.00512581181085,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.974240869572,3.17412460702E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.375779447805,0.0587156874834,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.677769327222,0.000306118637603,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.677769327222,0.00102291868188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.010930250684,0.677769330665,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,5,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00524762986259,0.557732354609,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.00941031876435,0.7174986967,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.00995010832881,0.950054186823,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0051192273405,0.983235983364,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.00865345525099,0.975923123901,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.00627725269229,0.997777708946,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0113699488957,0.682844690287,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,6.11859881397E-05,0.998523656209,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.00287609823827,0.879108503697,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.0215692356619,0.395430671369,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.107360761382,0.0172557604289,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.00523098192423,0.735621696617,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0340548291465,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0293474885099,0.497613429129,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,1.39109655756E-05,0.99995018979,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,1 mg/kg fidaxomicin,equivalent,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,3.05510449394E-06,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.883587017638,0.000957305725776,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.992739494893,0.00152391205062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.856116800311,0.00281256541261,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.975923123901,0.00201607605503,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.906724096182,0.00313557661711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.980775883689,0.000458605144594,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.1807332561,0.163639101766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.677769331873,0.0137129397742,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.987278522572,0.000180339814619,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999999998,1.69382172968E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.735136184029,0.00522902144858,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,3.94292867925E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.81239989383E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.107360761382,0.236878431711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25824219,25824219,25824219.txt,True,2015,sustained,10,3,"Clostridium difficile 
 
 infection",positive,SPF,C57BL/6,M,39,5-6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,50,250,50,mg/kg,QD,5,,vancomycin,untreated control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.107360761382,0.123750950774,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.677769327222,0.00545137302583,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.677769327222,0.00651951336706,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.583907197791,0.00980740192282,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.677769327222,0.00758886616443,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.597720223935,0.0121126391105,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.682844669796,0.00230031402521,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.107360761382,0.37577944379,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.441080771744,0.0446187225828,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.879108501663,0.00107252006303,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999996665296,2.63787573829E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.677769327223,0.0194497343853,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.999826094011,3.90811691693E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.997043861018,0.00015113394917,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.034318683874,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29483125,29483125,29483125.txt,True,2018,sustained,10,4,Clostridium difficile infection,positive,,Golden Syrian,F,42,6 weeks,100,100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,False,therapeutic,12,630,100,,spores,100,10,50,5,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.021223414827,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.525318098783,0.0464005689938,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.509973347184,0.0552345617961,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.40834363236,0.0761955620936,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.473736592047,0.0664723207157,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.418042524485,0.0861866805207,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.569785063275,0.0360868919806,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.0575150932476,0.655335424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.332023262504,0.262124339814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.655335424001,0.0154047144738,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.986523593859,4.95422873007E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.427549895839,0.0950548505842,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.688299373271,0.00362943353596,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.655335424,0.00777178849677,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0284349039389,0.67326543904,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,3,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,vancomycin,infected control,equal,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0171238015447,0.655335424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.883587017638,0.000957305725776,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.992739494893,0.00152391205062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.856116800311,0.00281256541261,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.975923123901,0.00201607605503,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.906724096182,0.00313557661711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.980775883689,0.000458605144594,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.1807332561,0.163639101766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.677769331873,0.0137129397742,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.987278522572,0.000180339814619,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999999998,1.69382172968E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.735136184029,0.00522902144858,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,3.94292867925E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.81239989383E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.107360761382,0.236878431711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,3,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.107360761382,0.123750950774,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.999384309704,0.000180125117527,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.999999999997,0.000297166581728,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.999984391394,0.000584880074995,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.999999998364,0.000423198492741,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.999999837012,0.000783095128506,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.999999333121,6.40453653625E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.37577944379,0.0629386617014,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.879108503697,0.00333090113716,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.999911798404,2.38011427832E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,8.75221105728E-10,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.928483590215,0.00117799635223,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,3.1823046736E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.97994459395E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.236878431711,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,2,Clostridium difficile,positive,SPF,C57BL/6,,56,7-9 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,1000000,CFU,vegetative,10^6,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.375779440166,0.0487182596466,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.883593755035,9.78263667859E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.979650337089,9.44130565127E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.811248549251,0.000276400478837,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.939288827829,0.000159184243101,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.850283519979,0.0003558747845,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.967700126259,2.54947950487E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.140716381584,0.140716381584,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.614579494187,0.00562798454593,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.967283745278,2.2255906191E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999999945,1.70347707782E-10,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.798243039563,0.00139601907511,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,2.02193401217E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.999999999998,1.54746941321E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0646156377445,0.236856614744,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,16,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,50000,,,10^4 to 10^5,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0371181273303,0.092743327088,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.503287120239,0.0276452221,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.503287120239,0.0368425065769,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.392490791939,0.0498534052604,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.503287120239,0.0438985265129,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.389446936581,0.0555809395879,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.503287120239,0.0197137509792,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.0378699340121,0.598119918703,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.282022931074,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.618875604913,0.00715025135486,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.986523863384,1.38736767081E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.503287120239,0.0659832385421,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.718788573165,0.00112796631893,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.67389475533,0.00294159124288,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0162602242515,0.673267961827,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,4,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,50,50,mg/kg,QD,1,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00984610550503,0.523349640452,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.991275056676,0.00144552244924,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.999996775008,0.00212140862541,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.993296915633,0.00396667661682,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.999921717457,0.00274875582555,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.999084257311,0.00471832128714,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.999830205499,0.000759741268632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.252909853113,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.796895742882,0.0123584761525,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.998655717315,0.00022082004445,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,4.08557388398E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.840148719434,0.00377113542152,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.25040853066E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,4.26355770807E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.167755383518,0.175580444246,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,100,50,mg/kg,QD,2,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.167755383518,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.999999478949,0.000168081738635,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,0.000411940427126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.999999999998,0.000740288413502,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.000636847058934,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.00105528532959,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.999999999999,0.000104966600809,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.598119918648,0.0378699341447,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.943845487661,0.00264923134452,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.999999403615,2.55116483494E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.49969131396E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.991056701187,0.000631786579289,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.02448936224E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,4.34874557735E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.503287120239,0.0573157336364,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,1,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.503287120239,0.0331143342628,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,2.5338692105E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,7.71836704139E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,0.000119663003789,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.000109985503194,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.000218513856631,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.1475587265E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918302019332,0.0100362494137,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.999935175646,0.000303322528493,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,2.23933750258E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,3.55585187218E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996927977,8.818918876E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,5.9224155054E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,4.14922522423E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836921569888,0.0104987945571,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,8,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390612648,0.00937692692963,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.812396334943,0.00921755591281,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.915556005561,0.0152039190304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.697768700486,0.0215500497326,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.834443262723,0.0178633702432,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.728648492746,0.0241250068319,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.919030908611,0.00561534169936,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.262124339814,0.276192638661,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.655335424,0.0474165363465,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.967280531745,0.00227275962629,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999999738,2.45541320246E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.694661227509,0.0267921944047,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.999999999995,0.000423197115335,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.999999997684,0.00101108847566,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.112590569125,0.321289879065,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,,,,,,,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0915506807532,0.262124339814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.812396334943,0.00921755591281,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.915556005561,0.0152039190304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.697768700486,0.0215500497326,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.834443262723,0.0178633702432,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.728648492746,0.0241250068319,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.919030908611,0.00561534169936,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.262124339814,0.276192638661,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.655335424,0.0474165363465,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.967280531745,0.00227275962629,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999999738,2.45541320246E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.694661227509,0.0267921944047,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.999999999995,0.000423197115335,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.999999997684,0.00101108847566,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.112590569125,0.321289879065,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,2,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0915506807532,0.262124339814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,0.000221486064863,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,0.000631816696197,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,0.000773453317412,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.000800836390257,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.00123754870125,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,0.000107209663624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918300414876,0.0169234590285,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517436,0.00179037452188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.78419747918E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,3.50169667119E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996927916,0.000615173534627,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,2.09604585938E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.05605505594E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836918746258,0.0284708828326,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,0,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,200,20,mg/kg,QD,10,,vancomycin,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390420458,0.0236768000807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,0.000221486064863,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,0.000631816696197,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,0.000773453317412,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.000800836390257,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.00123754870125,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,0.000107209663624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918300414876,0.0169234590285,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517436,0.00179037452188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.78419747918E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,3.50169667119E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996927916,0.000615173534627,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,2.09604585938E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.05605505594E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836918746258,0.0284708828326,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23217055,23217055,23217055.txt,True,2012,sustained,6,0,C. difficile,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,150,50,mg/kg,QD,3,,vancomycin,Negative Control,superior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390420458,0.0236768000807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.734394094106,0.000146176461363,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.725265516212,0.000114386446008,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.673247231393,0.00039571873962,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.680469518465,0.000183721211058,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.673247231393,0.000434396408,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.836909055827,4.19395017887E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.0828508339323,0.237341807399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.542870528796,0.00873761125505,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.890643107385,3.15170241643E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999708132,2.02124191338E-10,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.694671085821,0.0025011064143,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.999999692272,1.45581183844E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.999983660021,1.25195770906E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0253113047222,0.299794112895,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26832756,26832756,26832756.txt,True,2016,sustained,19,7,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,CFU,vegetative,10^5,20,100,20,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0101429673635,0.155708563604,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.9999999937,7.33768981584E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,2.2055211693E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,4.79801510671E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,3.43901349041E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,7.26283374878E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,3.03516004674E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.618761380051,0.0115264741669,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.979854211809,0.000274918242755,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.999999912424,9.1622033456E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,4.74372101844E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.9974989537,8.03333335394E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,5.16255953877E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,3.76277482832E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.464020907883,0.0175155751031,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,1,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.617368329912,0.0109153654356,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0336594324617,0.139749586254,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0240269241914,0.135225900335,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0145651331798,0.309586587668,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0210066418163,0.181872017956,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.014852120816,0.309586587668,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.036324835902,0.0850140945332,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.000545621197904,0.91830495767,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.0134791185953,0.425355199375,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.145235942282,0.0391373089283,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.416404570156,7.5464644742E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.0325221930911,0.30958659372,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.118200351236,0.00314533821031,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0932238046274,0.00845743948803,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,9.64094806633E-05,0.93966630029,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,17,12,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,vancomycin,Cadazolid,equivalent,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,3.73263626863E-06,0.995331632548,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0200204510268,0.474150387114,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0175190426678,0.617368329912,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0112741741259,0.627433452844,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0160605455154,0.617368329912,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.011629205955,0.658674313588,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0203296344113,0.436826466815,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.000185647646248,0.973338694698,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.00683164607837,0.732621293226,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.0551125800945,0.228705761991,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.183942948624,0.00281900026729,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.01184291562,0.617368335515,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0642272473694,0.0858875354981,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0518461828797,0.149778990053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,3.84741499484E-05,0.998420417575,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,11,9,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,6.72137697622E-06,0.99999994956,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.000239173605357,0.655845904659,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.000176263020516,0.811036138401,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,5.30047567917E-05,0.892999330454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.000107920212266,0.834473006088,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,5.97861471523E-05,0.959246511593,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.000304321567046,0.655845878116,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,6.49495974142E-07,0.999783101855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,5.30388230289E-05,0.867040764896,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.00352187075758,0.279394908196,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.0269259710744,0.00364579246182,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.000292157960658,0.742324892401,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.00353742278205,0.126175111111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.00239509798559,0.26382302617,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,4.5292534906E-08,0.999958816427,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,21,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,8.00327593642E-11,0.999999999834,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.263823026176,0.00514844693044,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.147635930857,0.00288293411577,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.114494987304,0.00896488676418,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.114494987304,0.00465605479624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.0866155455333,0.00843136524515,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.26382302617,0.00145188963752,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.004569213378,0.655870708529,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.114494990753,0.114494990753,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.571060939823,0.00143740191268,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.910807541132,3.51039379085E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.2138160358,0.0354425432401,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.570231260421,1.28549904533E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.483587723088,7.97809882975E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0010606168533,0.71520154355,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,24,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,5.03612158186E-05,0.675828807297,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0478171003278,0.140716379051,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.035511013852,0.140716379051,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0202773263289,0.20067670464,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0290437094797,0.140716379051,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.021028609314,0.219656177265,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0557447979303,0.0698123420347,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.000947845205576,0.821735320403,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.0200205775585,0.370034093354,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.174364574049,0.0319137022076,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.465715431882,4.97699265281E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.0460853098358,0.296523244128,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.151855223089,0.00264965767576,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.140716379051,0.00728439072777,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.000151732477538,0.932394172573,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,11,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,vancomycin,"CB-183,315",superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,8.53684064199E-06,0.981271568546,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.991275056676,0.00144552244924,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.999996775008,0.00212140862541,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.993296915633,0.00396667661682,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.999921717457,0.00274875582555,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.999084257311,0.00471832128714,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.999830205499,0.000759741268632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.252909853113,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.796895742882,0.0123584761525,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.998655717315,0.00022082004445,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,4.08557388398E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.840148719434,0.00377113542152,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.25040853066E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,4.26355770807E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.167755383518,0.175580444246,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,2,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.167755383518,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0230010977716,0.998407571039,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0296954214542,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0222449466194,0.99999999994,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0257118773631,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.0233371177815,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0295420180488,0.999830200405,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.000526138879969,0.999996696989,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.00936747704883,0.998409195869,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.0330684227158,0.849210784036,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.0917941808941,0.145640752308,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.0190604384195,0.99105643311,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0605643340165,0.996906967859,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0559127460232,0.999888204186,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.000135693104486,0.999999944542,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24514098,24514098,24514098.txt,True,2014,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,98,98g,hamster,inhibitor of type II topoisomerase enzymes,clindamycin+challenge,,cumulative mortality,True,therapeutic,53,B1,53,,spores,53,12.5,50,6.25,mg/kg,BID,4,,vancomycin,untreated control,superior,,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000152128815653,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,2.934718534E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,1.02496565549E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,1.95630837358E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,1.5920781881E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,3.4140835217E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.13100594665E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918303070876,0.00311452342953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517694,9.23844316317E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.8138267133E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.06753907807E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996928035,1.83136331463E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.70987242554E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.46940498032E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836923035894,0.00735075276842,inconclusive
https://pubmed.ncbi.nlm.nih.gov/27527088,27527088,27527088.txt,True,2016,sustained,10,0,Clostridium difficile,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,630,680,CFU,spores,680,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,2.934718534E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,1.02496565549E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,1.95630837358E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,1.5920781881E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,3.4140835217E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.13100594665E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918303070876,0.00311452342953,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517694,9.23844316317E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.8138267133E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.06753907807E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996928035,1.83136331463E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.70987242554E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.46940498032E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836923035894,0.00735075276842,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.999999970696,2.15718113533E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,6.05521758594E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,0.000110518336045,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,8.05645448449E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.000184263425005,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.08027896644E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.677769329638,0.0175834392983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.979854010997,0.000636822335281,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.999999912423,2.40123973608E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,3.46280741376E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.99749892872,0.000159199099624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,2.63592462763E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.80006004669E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.45508328839,0.025317169803,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,1,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,vancomycin,vehicle control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.677769327222,0.014014203902,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.999975996476,0.00175274681286,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,0.00323164867599,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.999999946041,0.00517143528708,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.00442706820572,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.999999999994,0.00635032994074,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.999999997608,0.00103627682418,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.408976234433,0.0847590189649,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.901107711616,0.00929389423205,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.999981133033,0.000239791702415,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,7.97872549527E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.972651082971,0.00476585282167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,3.13719214481E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,0.000131834137949,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.296862395987,0.116080072553,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22203600,22203600,22203600.txt,True,2012,sustained,6,1,C. difficile disease,positive,,Golden Syrian,F,,,85,80-90g,hamster,"selectively inhibits the replication-specific DNA 
 polymerase of Clostridium difficile",clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,87,VPI 10463,5000000,CFU,spores,0.5x10^7,100,300,50,mg/kg,BID,3,,vancomycin,control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.418847646398,0.078024806036,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.883587017638,0.000957305725776,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.992739494893,0.00152391205062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.856116800311,0.00281256541261,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.975923123901,0.00201607605503,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.906724096182,0.00313557661711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.980775883689,0.000458605144594,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.1807332561,0.163639101766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.677769331873,0.0137129397742,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.987278522572,0.000180339814619,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999999998,1.69382172968E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.735136184029,0.00522902144858,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,3.94292867925E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.81239989383E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.107360761382,0.236878431711,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,50,300,50,mg/kg,QD,6,,vancomycin,metronidazole,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.107360761382,0.123750950774,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.738081263263,0.000550274171921,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.756147658958,0.000648451547747,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.69815548911,0.00156898805281,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.703105208861,0.000892048826293,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.69815548911,0.00172184581979,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.826777705424,0.000196250950265,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.10650805083,0.217193217948,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.542861041758,0.0136316675194,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.925389441949,0.000109969295431,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.999999979321,3.75091798998E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.69815549346,0.00488845915795,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.999999986821,4.87474641858E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.999998019651,2.7335641351E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0439727691551,0.291678951841,inconclusive
https://pubmed.ncbi.nlm.nih.gov/15388461,15388461,15388461.txt,True,2004,sustained,14,5,C. difficile disease,positive,,Golden Syrian,,,,113,100-125g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,vancomycin,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.0239161470924,0.197887080361,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,2.5338692105E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,7.71836704139E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,0.000119663003789,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.000109985503194,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.000218513856631,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,1.1475587265E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918302019332,0.0100362494137,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.999935175646,0.000303322528493,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,2.23933750258E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,3.55585187218E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996927977,8.818918876E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,5.9224155054E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,4.14922522423E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836921569888,0.0104987945571,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,vancomycin,control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390612648,0.00937692692963,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,0.000505160699936,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,0.00181707480758,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,0.00266771554041,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.00194092993402,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.00317142919358,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,0.000366022513988,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918299674074,0.0366585833495,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.999935173712,0.00337572606505,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,9.40839461608E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.64507593739E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996927885,0.00126925525883,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.46565598029E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,6.04671143715E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.83691719473,0.0423896013565,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390324361,0.0339075859744,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.999999478949,0.000168081738635,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,0.000411940427126,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.999999999998,0.000740288413502,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.000636847058934,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.00105528532959,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.999999999999,0.000104966600809,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.598119918648,0.0378699341447,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.943845487661,0.00264923134452,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.999999403615,2.55116483494E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,1.49969131396E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.991056701187,0.000631786579289,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.02448936224E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,4.34874557735E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.503287120239,0.0573157336364,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,1,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.503287120239,0.0331143342628,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0230010977716,0.998407571039,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0296954214542,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0222449466194,0.99999999994,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0257118773631,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.0233371177815,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0295420180488,0.999830200405,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.000526138879969,0.999996696989,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.00936747704883,0.998409195869,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.0330684227158,0.849210784036,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.0917941808941,0.145640752308,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.0190604384195,0.99105643311,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0605643340165,0.996906967859,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0559127460232,0.999888204186,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.000135693104486,0.999999944542,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins B,inferior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000152128815653,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.796895739491,0.00557645195783,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.72681458235,0.0092158805775,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.627580394162,0.015362034604,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.694697001003,0.0114969695529,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.634207398104,0.0184479898378,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.796895739491,0.00440424088319,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.167755383518,0.351826481661,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.542860409137,0.0406447027941,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.849215279367,0.00124137571496,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.9999997081,8.09404584498E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.588809092896,0.0184771975143,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.999998232994,0.000118782218295,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.999929640906,0.000381078031285,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0573157332248,0.503287120239,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,vancomycin,Tiacumicins C,inferior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.042506984945,0.301011888388,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,1,0.000221486064863,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,0.000631816696197,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,1,0.000773453317412,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,1,0.000800836390257,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,1,0.00123754870125,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,1,0.000107209663624,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.918300414876,0.0169234590285,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.99993517436,0.00179037452188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.99999999999,1.78419747918E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,1,3.50169667119E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.999996927916,0.000615173534627,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,2.09604585938E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.05605505594E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836918746258,0.0284708828326,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,100,500,50,mg/kg,BID,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390420458,0.0236768000807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01085591-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,59,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,38,intervention:Specific,0.0273862903166,0.106827957623,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01987895-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,318,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0183851728892,0.107088362732,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02254967-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,179,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,106,intervention:Specific,0.0092463653825,0.20605391606,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01597505-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,280,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,171,intervention:Specific,0.0147815715252,0.155322956986,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01598311-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,292,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,172,intervention:Specific,0.0101920292716,0.20605391606,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02179658-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,108,therapeutic,Global cure at end of treatment,positive,participants,,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,71,intervention:Specific,0.0296539285825,0.0691616005314,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02743234-11,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,16,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,5,intervention:Specific,0.00027242794279,0.918306608685,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01222702-22,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,yes,22,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,12,intervention:Specific,0.010429142835,0.421199587645,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02218372-4,sustained,500,5000,125,mg,QID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,vancomycin,no,31,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,23,intervention:Specific,0.126352821712,0.0293572742098,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT00269399-4,sustained,500,5000,125,mg,QID,10,125 mg QID,antibiotic,vancomycin,no,73,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,63,intervention:Specific,0.411405223181,2.58173545742E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02092935-4,sustained,500,5000,125,mg,QID,10,,antibiotic,vancomycin,no,23,therapeutic,Sustained clinical response,positive,participants,inferior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,14,intervention:Specific,0.0295183588506,0.296531407361,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.0958255373536,0.00153236793356,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.0772694113292,0.00459967322965,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,4.70618979818E-05,0.941828784419,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33782498,33782498,33782498.txt,True,2021,sustained,20,14,Clostridioides difficile infections,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,clindamycin+challenge,survival,True,therapeutic,428,VA11,7500000,CFU,,7.5x10^6,20,100,20,mg/kg,QD,5,,vancomycin,Negative Control,superior,,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,1.10721715947E-06,0.990391761716,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,1,9.06560427134E-10,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.997417854638,3.33124722492E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.997404414783,4.2209891373E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.932391150619,0.000265019495659,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.025290472636,0.080588551033,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0433474194296,0.118219490075,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.0266196829337,0.206074451248,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0187149598823,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.025290472636,0.080588551033,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0433474194296,0.118219490075,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.0266196829337,0.206074451248,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0187149598823,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.025290472636,0.080588551033,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0433474194296,0.118219490075,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.0266196829337,0.206074451248,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0187149598823,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.025290472636,0.080588551033,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0433474194296,0.118219490075,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.0266196829337,0.206074451248,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0187149598823,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.025290472636,0.080588551033,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0433474194296,0.118219490075,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.0266196829337,0.206074451248,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0187149598823,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.00265539073863,0.0696410293685,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.00614753220333,0.118200354872,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.00336614033687,0.206053919961,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.00119453857504,0.455045107429,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.025290472636,0.080588551033,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0433474194296,0.118219490075,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.0266196829337,0.206074451248,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0187149598823,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.025290472636,0.080588551033,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0433474194296,0.118219490075,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.0266196829337,0.206074451248,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.0187149598823,0.455066923681,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,50,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,0.999967409929,1.1512639882E-31,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,50,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.999999994531,2.35800187977E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,50,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,0.999996285488,1.36723990145E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,50,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,0.997296701442,1.35515891079E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,114,110,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,1.9683795293E-11,0.00434547329818,equivalent
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,114,110,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,4.24497824716E-06,0.0577685622082,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,114,110,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,4.08470529812E-07,0.0969696483562,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,114,110,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,3.24748553123E-08,0.24438395678,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,107,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,Clinical Cure Rate (CCR) in the Modified Intent-to-treat Population,positive,Percentage of participants,Non-Inferiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,253,intervention:Specific,6.92713779662E-13,0.0557369173136,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,107,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-1,acute,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,2.35208528344E-07,0.118200351236,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,107,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-4,acute,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,18,intervention:Specific,1.43013650596E-08,0.20605391606,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,acute,107,107,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-7,acute,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,19,therapeutic,Modified clinical cure rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,16,intervention:Specific,8.71166863787E-10,0.455045103284,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,9.31501567122E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.997417854638,6.62651035366E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.9900158774,0.000209525605797,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.3,1.5,0.3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.87910850301,0.00301711617659,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.725332236431,0.00237894607797,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.879108502861,0.00201648664036,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.697482615826,0.00563839811652,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,10,50,10,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.501003926863,0.0399340632188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.0373262002047,0.389465250916,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.121831808787,0.168096931385,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.0691752900711,0.375779440167,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,100,500,100,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.0152420017974,0.716339371788,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.725332236431,0.00237894607797,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.879108502861,0.00201648664036,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.697482615826,0.00563839811652,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,12.5,62.5,12.5,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.501003926863,0.0399340632188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.270552113842,0.0373262002047,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.548855270908,0.0256246129666,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.411427043402,0.0566446438665,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,25,125,25,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.120149585625,0.271330393951,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,1,9.31501567122E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.997417854638,6.62651035366E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.9900158774,0.000209525605797,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,2,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,3,15,3,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.87910850301,0.00301711617659,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.411405223167,0.000620497997571,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.758216415315,0.00228211824496,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.629639534519,0.00573705877047,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,20,10,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,30,150,30,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.271307430883,0.0691616026258,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.270552113842,0.0373262002047,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.548855270908,0.0256246129666,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.411427043402,0.0566446438665,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,6,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,300,1500,300,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.120149585625,0.271330393951,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.725332236431,0.00237894607797,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.879108502861,0.00201648664036,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.697482615826,0.00563839811652,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,10,4,C. difficile disease,positive,,Golden Syrian,M,58,45-70 days,111,98-124g,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,50,250,50,mg/kg,QD,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.501003926863,0.0399340632188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,43,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,0.846382213211,1.32183519194E-16,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,43,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,0.990469798911,2.58411657363E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,43,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,0.839411489268,4.67038121936E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,43,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,0.2,1,0.1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,0.396266096437,0.00256607276503,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,114,105,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,3.0780939713E-17,0.951914834197,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,114,105,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,2.57711547168E-07,0.400028256478,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,114,105,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,4.89587035668E-09,0.62960462375,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,114,105,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,2,10,1,mg/kg,BID,5,,Cadazolid,vancomycin,equivalent,equivalent,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,1.64688156563E-11,0.99766981579,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,94,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01987895-3,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,no,302,therapeutic,"Sustained Cure Rate (SCR) in the Modified Intent-to-treat Population -  Sustained Cure is defined for each subject having Clinical 
Cure and no recurrence. SCR is the percentage of subjects with Sustained
 Cure. The main analysis is performed on the modified intent-to-treat 
set (mITT).",positive,Percentage of participants,Superiority,Wilson's score method,x,NCT01987895,Efficacy and Safety of Cadazolid Versus Vancomycin in Subjects With Clostridium Difficile - Associated Diarrhea,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01987895,198,intervention:Specific,9.87208235839E-14,0.725434207053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,94,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-13,sustained,500,5000,250,mg,BID,10,,antibiotic,Cadazolid,yes,17,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,13,intervention:Specific,2.16709055757E-05,0.309586587668,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,94,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-16,sustained,1000,10000,500,mg,BID,10,,antibiotic,Cadazolid,yes,20,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,14,intervention:Specific,9.89185832381E-07,0.468958445599,inconclusive
https://pubmed.ncbi.nlm.nih.gov/24277020,24277020,24277020.txt,True,2014,sustained,107,94,C. difficile disease,positive,,C57BL/6,F,70,8-12 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin, gentamicin, colistin, metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,spores,10^5,20,100,10,mg/kg,BID,5,,Cadazolid,Negative Control,superior,superior,,Y,True,NCT01222702-19,sustained,2000,20000,1000,mg,BID,10,,antibiotic,Cadazolid,yes,18,therapeutic,Modified sustained clinical response rate,positive,participants,,,https://aac.asm.org/content/59/10/6266,NCT01222702,"Efficacy, Safety and Tolerability of Cadazolid in Subjects With Clostridium Difficile Associated Diarrhea (CDAD)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01222702,10,intervention:Specific,6.05270333103E-09,0.92650678161,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,1,1.23965184037E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,1,1.91892093576E-12,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.963817932153,0.00236513731234,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,1,7.93139139534E-10,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.999999999989,5.17774797511E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.999999995902,3.35643585009E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.999135426541,0.000226429833951,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.999995933576,3.67124712305E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.999999942921,2.67635599996E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.999999999993,1.653620302E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,1,7.84994240845E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.999999991718,1.26050998175E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,1,1.75155650899E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.185632665902,0.122566652232,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.999999926926,2.64129155336E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.994443425306,5.85077144423E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.996096089743,5.42558301096E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.67778958681,0.0330463788713,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.879120833897,0.00178073799591,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.981938083623,0.000306609139631,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.999967372617,7.86195109146E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,1,4.82743006525E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,acute,10,10,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0289097741278,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0224089425042,0.226573450454,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,5.22771360222E-06,0.999999894766,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.011197506767,0.771530077299,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0117264309518,0.616667828062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0352760627035,0.274849562498,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00140138966724,0.967202186399,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00348648024387,0.879120833656,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.00886472512791,0.648143344715,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0510179377448,0.14071638111,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0142714249356,0.781670732499,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.99999968323,7.98753302708E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.999999999869,3.73206591814E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.262124339814,0.263846547415,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.999994503998,0.000181071541437,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.994443204271,0.00103584247069,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.996095939533,0.000491475815062,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.655352627716,0.0792494904652,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.870146524517,0.0106699950389,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.938939328681,0.00234678413103,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.999967371336,8.95139057857E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.999999999287,6.96989784309E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.987961837593,0.000117274405424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.966768057423,8.05217194245E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.0518231086099,0.655335424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.702673739069,0.00178221091605,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.698387532465,0.0074524560827,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.927435531311,0.0038504810142,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.377260953509,0.26212434064,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.655335426236,0.0448722437799,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.713550587215,0.0132171905153,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.973337386879,0.000722611391344,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.781661999212,0.000897002337981,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0682030903474,0.0985671094641,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0630493353772,0.262124339814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.000146930566248,0.999999894762,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.0389232503879,0.771520947441,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0433969931875,0.655335424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0924497104064,0.274866568797,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00918193357553,0.96665198584,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.025260943484,0.870146524517,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.0384931001234,0.655335424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.106214726277,0.140729044828,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,6,6,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0478608777554,0.781661999212,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.100762375551,0.100762377552,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0816692732814,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.000658093206647,0.999999894761,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.0570077474561,0.771518662632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0553548547682,0.616658708441,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.123325620755,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.0189870662628,0.966651914166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.0324980893798,0.870145249948,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.0515504999168,0.648139123829,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.143065328273,0.140726933807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,5,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0671890987639,0.78165981581,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.999999999999,2.50519866212E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,1,1.37904658499E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.459853525737,0.119800035163,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,1,5.42178299484E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.999986427208,0.000295063815983,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,fidaxomicin,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.999937779394,0.000163876914376,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,fidaxomicin,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.851957965037,0.0339093263003,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.988387442063,0.00454381933869,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.999214751529,0.00107819852282,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.99999975197,2.72936616331E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,acute,5,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,1,2.38502352477E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.99999999986,2.51953056107E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,1,5.44484344812E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.999958812884,8.47723247582E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.992995107249,0.000382228259469,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,6.59927467386E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.999999897559,3.4084860461E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,1,1.92688452233E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999999999967,3.36045422646E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.04,0.2,0.04,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,1,1.02195013068E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.99999999986,2.51953056107E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,1,5.44484344812E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.999958812884,8.47723247582E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.992995107249,0.000382228259469,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,6.59927467386E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.999999897559,3.4084860461E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,1,1.92688452233E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999999999967,3.36045422646E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,0,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,0.2,1,0.2,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,1,1.02195013068E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.879108501663,0.0010789857947,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.993937147798,0.000320712227269,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.677769332779,0.0122529711865,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.501639897227,0.0549666493307,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,1.11951382367E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.993629595207,0.000204313999452,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.999937782485,3.42346226117E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999886735172,1.3702374518E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,3,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,1,5,1,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.999989409379,6.66168162498E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.0113934644923,0.677769327224,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.011839178406,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.00236513702851,0.910816362139,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.00130874089909,0.906202141736,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.144954273399,0.000487463306522,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.135155459273,0.135155459273,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.375779442159,0.0239370476641,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.167125767364,0.043724762229,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33495229,33495229,33495229.txt,True,2021,sustained,10,9,Clostridioides difficile,positive,SPF,Golden Syrian,M,39,5-6 weeks,,,hamster,,challenge+clindamycin,challenge+clindamycin,survival,True,therapeutic,87,VPI 10463,1000000,CFU,,10^6,5,25,5,mg/kg,QD,5,,fidaxomicin,1 mg/kg vancomycin,equivalent,equivalent,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.0189858670375,0.611871849864,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.879108501663,0.0010789857947,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.993937147798,0.000320712227269,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.677769332779,0.0122529711865,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.501639897227,0.0549666493307,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,1.11951382367E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.993629595207,0.000204313999452,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.999937782485,3.42346226117E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999886735172,1.3702374518E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,3,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.999989409379,6.66168162498E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.99999999986,2.51953056107E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,1,5.44484344812E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.999958812884,8.47723247582E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.992995107249,0.000382228259469,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,6.59927467386E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.999999897559,3.4084860461E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,1,1.92688452233E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999999999967,3.36045422646E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,20,100,10,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,1,1.02195013068E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.677769327224,0.00542074445218,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.693410242497,0.00157497219791,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.459863446789,0.0400172957238,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.375779442522,0.117793552882,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.999999999998,2.86820340263E-10,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.967203089324,0.000731021731182,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.99941860716,1.99008316248E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.995759280971,6.12742637646E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,4,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.906776925797,0.00042834615444,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.99999999986,2.51953056107E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,1,5.44484344812E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.999958812884,8.47723247582E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.992995107249,0.000382228259469,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,6.59927467386E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.999999897559,3.4084860461E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,1,1.92688452233E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999999999967,3.36045422646E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,0,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,fidaxomicin,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,1,1.02195013068E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.0113934644923,0.677769327224,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.011839178406,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.00236513702851,0.910816362139,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.00130874089909,0.906202141736,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.144954273399,0.000487463306522,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.135155459273,0.135155459273,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.375779442159,0.0239370476641,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.167125767364,0.043724762229,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,2,10,1,mg/kg,BID,5,,fidaxomicin,SMT19969 12.5 mg/kg BID,eqivalent,eqivalent,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.0189858670375,0.611871849864,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.0113934644923,0.677769327224,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.011839178406,0.677769327222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.00236513702851,0.910816362139,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.00130874089909,0.906202141736,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.144954273399,0.000487463306522,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.135155459273,0.135155459273,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.375779442159,0.0239370476641,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.167125767364,0.043724762229,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,5,25,2.5,mg/kg,BID,5,,fidaxomicin,vehicle control,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.0189858670375,0.611871849864,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.99999999986,0.00014125640302,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,1,8.75299134488E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.999958811246,0.00136406723816,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.992994842689,0.00507652914607,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,9.12546910285E-13,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.999999897555,8.35447057517E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,1,1.90457083035E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999999999967,4.1339123471E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.03,0.15,0.03,mg/kg,QD,5,,fidaxomicin,vancomycin 100 mg/kg,eqivalent,,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,1,2.82178985531E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.999515582799,0.00131773825822,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.999999999517,0.000786737826806,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.910812890071,0.00928874052021,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.747308341603,0.0264187635728,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,8.05055979093E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.999922048775,0.000150546185538,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.999999995902,5.3921643583E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999999942919,1.03015989831E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,1,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,30000,,spores,3x10^4,0.3,1.5,0.3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,1,0.000255677117361,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.737259519872,0.0230791521878,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.737259519872,0.0161918922523,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.459853525737,0.0942778828878,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.327659523707,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.999999999998,8.18332689276E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.967201531992,0.00400331000429,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.999995471983,0.000264402579873,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999214751481,0.000522772882424,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,2,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,2,10,1,mg/kg,BID,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.906772264507,0.0084220050958,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.99999999986,0.00049518133394,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,1,0.000276047600388,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.999958810835,0.00231794518178,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.992994772798,0.00979786544957,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,1,1.120426169E-11,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.999999897554,2.61162709547E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,1,7.58443242806E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.999999999967,1.73087495156E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,5,0,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,1,1,1,mg/kg,QD,1,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,1,0.000114290247491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,fidaxomicin,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.655335424,0.04538664006,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.655335424,0.0259064104936,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.2638558584,0.262124339814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,fidaxomicin,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.262124339815,0.292595690611,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,fidaxomicin,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.999990645081,2.33047601126E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,fidaxomicin,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.901115904169,0.00857312058776,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,fidaxomicin,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.999418584085,0.000624497128918,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,fidaxomicin,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.938939328681,0.00103583992806,inconclusive
https://pubmed.ncbi.nlm.nih.gov/29439962,29439962,29439962.txt,True,2018,sustained,6,3,Clostridium difficile infection,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,2009155,40000,,spores,4x10^4,3,15,3,mg/kg,QD,5,,fidaxomicin,Negative Control,superior,,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,fidaxomicin,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.655335424,0.0147176287132,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,0,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,1,6,1,mg/kg,QD,6,,metronidazole,control,superior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/33045352,33045352,33045352.txt,True,2020,acute,10,6,Clostridioides difficile infection,positive,,C57BL/6,F,42,6 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,True,therapeutic,87,VPI 10463,800000,CFU,spores,8x10^5,10,60,10,mg/kg,QD,6,,metronidazole,vancomycin 10 mg/kg,inferior,,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00112444134758,0.768942047761,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,metronidazole,infected control,inferior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00273555617224,0.965438492169,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,acute,10,5,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,metronidazole,Negative Control,superior,superior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00524762986259,0.557732354609,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,acute,6,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,metronidazole,Positive Control,equivalent,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000357148140694,0.999999996787,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,150,900,150,mg/kg,QD,6,,metronidazole,vancomycin,inferior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/11451694,11451694,11451694.txt,True,2001,acute,10,10,C. difficile disease,positive,,,,,,,,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,,HUC 2-4,1000000,CFU,,10^6,210,1050,210,mg/kg,QD,5,,metronidazole,Saline (control),equivalent,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,2.98171617854E-07,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22869573,22869573,22869573.txt,True,2012,acute,6,6,C. difficile disease,positive,,Golden Syrian,,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,12,ATCC 43596,50000000,CFU,,5x10^7,300,1500,150,mg/kg,BID,5,,metronidazole,Negative Control,superior,equivalent,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,4.53023962064E-05,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,14,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-FD,Positive Control,inferior,,,Y,True,NCT02743234-1,acute,,,,,,,,FMT,FMT-FD,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,superior,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,17,intervention:Variation,0.114494990141,0.0853341360729,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,14,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-FD,Positive Control,inferior,,,Y,True,NCT01914731-1,acute,,,,,,,,FMT,FMT-FD,no,20,therapeutic,clinical resolution of diarrhea after the first administration of FMT,positive,participants,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,14,intervention:Variation,0.0940145824359,0.0940145824359,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,14,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-FD,Positive Control,inferior,,,Y,True,NCT01914731-2,acute,,,,,,,,FMT,FMT-FD,no,6,therapeutic,resolution of diarrhea after the second treatment,positive,participants,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,5,intervention:Variation,0.412218104746,0.0955015712177,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,11,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-G10,Positive Control,inferior,,,Y,True,NCT02743234-1,acute,,,,,,,,FMT,FMT-G10,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,superior,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,17,intervention:Variation,0.459867529635,0.00997910238861,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,11,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-G10,Positive Control,inferior,,,Y,True,NCT01914731-1,acute,,,,,,,,FMT,FMT-G10,no,20,therapeutic,clinical resolution of diarrhea after the first administration of FMT,positive,participants,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,14,intervention:Variation,0.422796581581,0.0127648868593,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,11,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-G10,Positive Control,inferior,,,Y,True,NCT01914731-2,acute,,,,,,,,FMT,FMT-G10,no,6,therapeutic,resolution of diarrhea after the second treatment,positive,participants,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,5,intervention:Variation,0.663210708165,0.027840074053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,12,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-G80,Positive Control,inferior,,,Y,True,NCT02743234-1,acute,,,,,,,,FMT,FMT-G80,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,superior,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,17,intervention:Variation,0.274872771056,0.0220347561491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,12,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-G80,Positive Control,inferior,,,Y,True,NCT01914731-1,acute,,,,,,,,FMT,FMT-G80,no,20,therapeutic,clinical resolution of diarrhea after the first administration of FMT,positive,participants,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,14,intervention:Variation,0.285456089805,0.0265193176586,inconclusive
https://pubmed.ncbi.nlm.nih.gov/32501140,32501140,32501140.txt,True,2020,acute,20,12,Clostridioides difficile infection,positive,,C57BL/6,F,46,6-7 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,27,R20291,8000,CFU,vegetative,8x10^3,,,,,,,,FMT-G80,Positive Control,inferior,,,Y,True,NCT01914731-2,acute,,,,,,,,FMT,FMT-G80,no,6,therapeutic,resolution of diarrhea after the second treatment,positive,participants,success,95% CI,https://doi.org/10.1001/jama.2014.13875,NCT01914731,Fecal Microbiota Transplant for Relapsing Clostridium Difficile Infection in Adults and Children Using a Frozen Encapsulated Inoculum,All,"Child, Adult, Older Adult","7 Years to 90 Years Â (Child, Adult, Older Adult)",Phase 1,https://ClinicalTrials.gov/show/NCT01914731,5,intervention:Variation,0.655335428669,0.0477135690304,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25486992,25486992,25486992.txt,True,2015,sustained,5,4,Clostridium difficile infection,positive,,C57BL/6,,49,6-8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",C. difficile spores,survival,False,therapeutic,27,UK1,100000,,spores,10^5,5,25,5,mg/kg,QD,5,,actoxumab-bezlotoxumab,Negative Control,superior,,,Y,True,NCT00350298-3,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,actoxumab-bezlotoxumab,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,intervention:Specific,1.08796330141E-10,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25486992,25486992,25486992.txt,True,2015,sustained,5,4,Clostridium difficile infection,positive,,C57BL/6,,49,6-8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",C. difficile spores,survival,False,therapeutic,27,UK1,100000,,spores,10^5,5,25,5,mg/kg,QD,5,,actoxumab-bezlotoxumab,Negative Control,superior,,,Y,True,NCT01513239-3,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,intervention:Variation,0.345619222702,0.000536309673905,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25486992,25486992,25486992.txt,True,2015,sustained,5,4,Clostridium difficile infection,positive,,C57BL/6,,49,6-8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",C. difficile spores,survival,False,therapeutic,27,UK1,100000,,spores,10^5,5,25,5,mg/kg,QD,5,,actoxumab-bezlotoxumab,Negative Control,superior,,,Y,True,NCT01241552-7,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,actoxumab-bezlotoxumab,no,383,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,not superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,323,intervention:Variation,0.3454243807,0.000595181178338,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25486992,25486992,25486992.txt,True,2015,sustained,5,5,Clostridium difficile infection,positive,,C57BL/6,,49,6-8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",C. difficile spores,survival,False,therapeutic,27,UK1,100000,,spores,10^5,50,50,50,mg/kg,QD,1,,actoxumab-bezlotoxumab,N297Q mutant actoxumab-bezlotoxumab,inferior,,,Y,True,NCT00350298-3,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,actoxumab-bezlotoxumab,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,intervention:Specific,7.99246153393E-13,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25486992,25486992,25486992.txt,True,2015,sustained,5,5,Clostridium difficile infection,positive,,C57BL/6,,49,6-8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",C. difficile spores,survival,False,therapeutic,27,UK1,100000,,spores,10^5,50,50,50,mg/kg,QD,1,,actoxumab-bezlotoxumab,N297Q mutant actoxumab-bezlotoxumab,inferior,,,Y,True,NCT01513239-3,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,actoxumab-bezlotoxumab,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,intervention:Variation,0.100176017928,0.0559127460232,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25486992,25486992,25486992.txt,True,2015,sustained,5,5,Clostridium difficile infection,positive,,C57BL/6,,49,6-8 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",C. difficile spores,survival,False,therapeutic,27,UK1,100000,,spores,10^5,50,50,50,mg/kg,QD,1,,actoxumab-bezlotoxumab,N297Q mutant actoxumab-bezlotoxumab,inferior,,,Y,True,NCT01241552-7,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,actoxumab-bezlotoxumab,no,383,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,not superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,323,intervention:Variation,0.09915203493,0.0598408727332,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,acute,6,5,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,100,1000,50 vancomycin + 50 metronidazole,mg/kg,QD,10,50 mg/kg QD + 50 mg/kg QD for 10 days,vancomycin + metronidazole,infected control,inferior,inferior,,Y,True,NCT02589847-2,acute,,,,,,,,antibiotic,vancomycin + metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000357148140694,0.999999996787,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,100,1000,50 vancomycin + 50 metronidazole,mg/kg,QD,10,50 mg/kg QD + 50 mg/kg QD for 10 days,vancomycin + metronidazole,infected control,inferior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,vancomycin + metronidazole,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.398565062407,0.0278943907855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,100,1000,50 vancomycin + 50 metronidazole,mg/kg,QD,10,50 mg/kg QD + 50 mg/kg QD for 10 days,vancomycin + metronidazole,infected control,inferior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,vancomycin + metronidazole,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.356046601274,0.0490302487558,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,100,1000,50 vancomycin + 50 metronidazole,mg/kg,QD,10,50 mg/kg QD + 50 mg/kg QD for 10 days,vancomycin + metronidazole,infected control,inferior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,vancomycin + metronidazole,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0054259764279,0.932388458582,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,100,1000,50 vancomycin + 50 metronidazole,mg/kg,QD,10,50 mg/kg QD + 50 mg/kg QD for 10 days,vancomycin + metronidazole,infected control,inferior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,vancomycin + metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00273555617224,0.965438492169,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,metronidazole,infected control,inferior,inferior,,Y,True,NCT00182429-1,sustained,1500,15000,500,mg,TID,10,,antibiotic,metronidazole,no,20,therapeutic,Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).,positive,participants,,,https://academic.oup.com/cid/article/43/5/547/503445,NCT00182429,Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment,All,"Child, Adult, Older Adult","14 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00182429,4,intervention:Specific,0.00151049487737,0.990015487293,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,metronidazole,infected control,inferior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,metronidazole,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.398565062407,0.0278943907855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,metronidazole,infected control,inferior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,metronidazole,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.356046601274,0.0490302487558,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,metronidazole,infected control,inferior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,metronidazole,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.0054259764279,0.932388458582,inconclusive
https://pubmed.ncbi.nlm.nih.gov/26568840,26568840,26568840.txt,True,2015,sustained,6,4,C. difficile infection (CDI),positive,,C57BL/6J,F,49,6-8 weeks,19,18-19g,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,200000,CFU,,2x10^5,50,500,50,mg/kg,QD,10,,metronidazole,infected control,inferior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00273555617224,0.965438492169,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,5,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,metronidazole,Negative Control,superior,superior,,Y,True,NCT00182429-1,sustained,1500,15000,500,mg,TID,10,,antibiotic,metronidazole,no,20,therapeutic,Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).,positive,participants,,,https://academic.oup.com/cid/article/43/5/547/503445,NCT00182429,Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment,All,"Child, Adult, Older Adult","14 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00182429,4,intervention:Specific,0.00279845525499,0.736488419164,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,5,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,metronidazole,Negative Control,superior,superior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,metronidazole,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.677769327222,0.000306118637603,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,5,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,metronidazole,Negative Control,superior,superior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,metronidazole,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.677769327222,0.00102291868188,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,5,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,metronidazole,Negative Control,superior,superior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,metronidazole,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.010930250684,0.677769330665,inconclusive
https://pubmed.ncbi.nlm.nih.gov/31849218,31849218,31849218.txt,True,2020,sustained,10,5,Clostridium difficile infection,positive,,C57/B6,F,49,6-8 weeks,,,mouse,,cefoperazone + clindamycin + challenge,,cumulative mortality,False,therapeutic,87,VPI 10463,8600000,CFU,,8.6x10^6,20,140,20,mg/kg,QD,7,,metronidazole,Negative Control,superior,superior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.00524762986259,0.557732354609,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,metronidazole,Positive Control,equivalent,inferior,,Y,True,NCT00182429-1,sustained,1500,15000,500,mg,TID,10,,antibiotic,metronidazole,no,20,therapeutic,Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).,positive,participants,,,https://academic.oup.com/cid/article/43/5/547/503445,NCT00182429,Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment,All,"Child, Adult, Older Adult","14 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00182429,4,intervention:Specific,0.000154151925456,0.999984829411,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,metronidazole,Positive Control,equivalent,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,metronidazole,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,0.140409269173,0.262124339814,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,metronidazole,Positive Control,equivalent,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,metronidazole,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,0.113125445822,0.309046759256,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,metronidazole,Positive Control,equivalent,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,metronidazole,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.00072424198936,0.999690388727,inconclusive
https://pubmed.ncbi.nlm.nih.gov/23147742,23147742,23147742.txt,True,2012,sustained,6,5,Clostridium difficile infection,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,100000,,,10^5,20,100,20,mg/kg,QD,5,,metronidazole,Positive Control,equivalent,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.000357148140694,0.999999996787,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,150,900,150,mg/kg,QD,6,,metronidazole,vancomycin,inferior,inferior,,Y,True,NCT00182429-1,sustained,1500,15000,500,mg,TID,10,,antibiotic,metronidazole,no,20,therapeutic,Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).,positive,participants,,,https://academic.oup.com/cid/article/43/5/547/503445,NCT00182429,Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment,All,"Child, Adult, Older Adult","14 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00182429,4,intervention:Specific,0.677769327223,0.0119413371642,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,150,900,150,mg/kg,QD,6,,metronidazole,vancomycin,inferior,inferior,,Y,True,NCT01513239-6,sustained,,,,,,,,control,metronidazole,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,1.70987242554E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,150,900,150,mg/kg,QD,6,,metronidazole,vancomycin,inferior,inferior,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,metronidazole,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.46940498032E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,150,900,150,mg/kg,QD,6,,metronidazole,vancomycin,inferior,inferior,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,metronidazole,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836923035894,0.00735075276842,inconclusive
https://pubmed.ncbi.nlm.nih.gov/10952564,10952564,10952564.txt,True,2000,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,,TTU 614,100000,,,10^5,150,900,150,mg/kg,QD,6,,metronidazole,vancomycin,inferior,inferior,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390804817,0.00410477893053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/11451694,11451694,11451694.txt,True,2001,sustained,10,2,C. difficile disease,positive,,,,,,,,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,,HUC 2-4,1000000,CFU,,10^6,210,1050,210,mg/kg,QD,5,,metronidazole,Saline (control),equivalent,equivalent,,Y,True,NCT00182429-1,sustained,1500,15000,500,mg,TID,10,,antibiotic,metronidazole,no,20,therapeutic,Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).,positive,participants,,,https://academic.oup.com/cid/article/43/5/547/503445,NCT00182429,Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment,All,"Child, Adult, Older Adult","14 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00182429,4,intervention:Specific,0.107360761382,0.140962095735,inconclusive
https://pubmed.ncbi.nlm.nih.gov/11451694,11451694,11451694.txt,True,2001,sustained,10,2,C. difficile disease,positive,,,,,,,,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,,HUC 2-4,1000000,CFU,,10^6,210,1050,210,mg/kg,QD,5,,metronidazole,Saline (control),equivalent,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,metronidazole,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,3.1823046736E-07,inconclusive
https://pubmed.ncbi.nlm.nih.gov/11451694,11451694,11451694.txt,True,2001,sustained,10,2,C. difficile disease,positive,,,,,,,,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,,HUC 2-4,1000000,CFU,,10^6,210,1050,210,mg/kg,QD,5,,metronidazole,Saline (control),equivalent,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,metronidazole,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.97994459395E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/11451694,11451694,11451694.txt,True,2001,sustained,10,2,C. difficile disease,positive,,,,,,,,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,,HUC 2-4,1000000,CFU,,10^6,210,1050,210,mg/kg,QD,5,,metronidazole,Saline (control),equivalent,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,metronidazole,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.236878431711,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/11451694,11451694,11451694.txt,True,2001,sustained,10,2,C. difficile disease,positive,,,,,,,,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,,HUC 2-4,1000000,CFU,,10^6,210,1050,210,mg/kg,QD,5,,metronidazole,Saline (control),equivalent,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.375779440166,0.0487182596466,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22869573,22869573,22869573.txt,True,2012,sustained,6,0,C. difficile disease,positive,,Golden Syrian,,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,12,ATCC 43596,50000000,CFU,,5x10^7,300,1500,150,mg/kg,BID,5,,metronidazole,Negative Control,superior,equivalent,,Y,True,NCT00182429-1,sustained,1500,15000,500,mg,TID,10,,antibiotic,metronidazole,no,20,therapeutic,Resolution of symptoms in each treatment arm (in days) up to 40 days (measured using daily stool and symptom diary).,positive,participants,,,https://academic.oup.com/cid/article/43/5/547/503445,NCT00182429,Efficacy of Metronidazole Versus Metronidazole and Rifampin in CDAD Treatment,All,"Child, Adult, Older Adult","14 Years and older Â (Child, Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00182429,4,intervention:Specific,0.655335424,0.0477110475687,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22869573,22869573,22869573.txt,True,2012,sustained,6,0,C. difficile disease,positive,,Golden Syrian,,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,12,ATCC 43596,50000000,CFU,,5x10^7,300,1500,150,mg/kg,BID,5,,metronidazole,Negative Control,superior,equivalent,,Y,True,NCT01513239-6,sustained,,,,,,,,control,metronidazole,no,378,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,,x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,281,intervention:Variation,1,2.09604585938E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22869573,22869573,22869573.txt,True,2012,sustained,6,0,C. difficile disease,positive,,Golden Syrian,,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,12,ATCC 43596,50000000,CFU,,5x10^7,300,1500,150,mg/kg,BID,5,,metronidazole,Negative Control,superior,equivalent,,Y,True,NCT01241552-12,sustained,,,,,,,,antibiotic,metronidazole,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,286,intervention:Variation,1,1.05605505594E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22869573,22869573,22869573.txt,True,2012,sustained,6,0,C. difficile disease,positive,,Golden Syrian,,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,12,ATCC 43596,50000000,CFU,,5x10^7,300,1500,150,mg/kg,BID,5,,metronidazole,Negative Control,superior,equivalent,,Y,True,NCT02148601-2,sustained,,,,,,,,antibiotic,metronidazole,no,19,therapeutic,Disappearance of clinical symptoms linked to C. difficile infection [ Time Frame: 10 weeks ],positive,participants,,,https://onlinelibrary.wiley.com/doi/full/10.1111/apt.13144,NCT02148601,Fecal Microbiota Transplantation by Colonoscopy for Recurrent C. Difficile Infection,All,"Adult, Older Adult","18 Years to 95 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02148601,5,intervention:Variation,0.836918746258,0.0284708828326,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22869573,22869573,22869573.txt,True,2012,sustained,6,0,C. difficile disease,positive,,Golden Syrian,,,,90,80-100g,hamster,,clindamycin+challenge,,cumulative mortality,False,therapeutic,12,ATCC 43596,50000000,CFU,,5x10^7,300,1500,150,mg/kg,BID,5,,metronidazole,Negative Control,superior,equivalent,,Y,True,NCT02589847-4,sustained,,,,,,,,antibiotic,metronidazole,no,75,therapeutic,Number of Participants Who Were CDI-diarrhea Free Through 8 Weeks,positive,participants,,,x,NCT02589847,Microbiota Restoration Therapy for Recurrent Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02589847,23,intervention:Variation,0.990390420458,0.0236768000807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22585229,22585229,22585229.txt,True,2012,sustained,8,2,C. difficile disease,positive,,C57BL/6,M,56,8 weeks,,,mouse,,"vancomycin,colistin,gentamicin,metronidazole+clindamycin+challenge",,cumulative mortality,False,therapeutic,87,VPI 10463,10000,CFU,,10^4,20,100,20,mg/kg,QD,5,,Nitazoxanide,Negative Control,superior,,,Y,True,NCT00304356-1,sustained,1000,,500,mg,BID,,,other,Nitazoxanide,no,27,therapeutic,Nitazoxanide [ Time Frame: 30 days ] - stopping of diarrhea,positive,participants,,,x,NCT00304356,Compassionate Use of Nitazoxanide for the Treatment of Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00304356,27,intervention:Specific,1,3.96477808529E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/18848941,18848941,18848941.txt,True,2008,sustained,12,5,C. difficile disease,positive,,C57BL/6,F,63,9 weeks,,,mouse,,"kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge","kanamycin,gentamicin,colistin,metronidazole,vancomycin+clindamycin+challenge",cumulative mortality,True,prophylactic,87,VPI 10463,10000,CFU,,10^4,50,50,50,mg/kg,QD,1,,vancomycin,control,superior,superior,,Y,True,NCT02951702-1,sustained,125,,125,mg,QD,,unspecified duration,antibiotic,vancomycin,no,17,prophylactic,Clostridium Difficile Infection Occurrence [ Time Frame: Within 4 weeks from the completion of antibiotic treatment ],positive,participants,,,x,NCT02951702,Oral Vancomyin for Primary Clostridium Difficile Infection Prophylaxis in Patients Receiving High-Risk Antibiotics,All,Older Adult,65 Years and older Â (Older Adult),Phase 4,https://ClinicalTrials.gov/show/NCT02951702,17,intervention:Specific,0.999990832135,1.21350861183E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,33,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01085591-1,acute,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,intervention:Specific,0.00141351615243,0.00274985938968,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,33,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01085591-3,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,intervention:Specific,0.000341144053524,0.0436426993929,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,33,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01597505-1,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,intervention:Specific,8.79996178581E-05,0.328978193057,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,33,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01598311-1,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,intervention:Specific,0.000275805432614,0.0274927203653,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,32,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01085591-1,acute,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,intervention:Specific,0.000510588168649,0.0074569265767,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,32,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01085591-3,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,intervention:Specific,0.000103976050016,0.113566037743,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,32,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01597505-1,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,intervention:Specific,3.65997601729E-05,0.699979238679,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,32,32,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01598311-1,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,intervention:Specific,0.000110143214991,0.102302371532,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01085591-1,acute,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,intervention:Specific,0.0128060752964,0.0101132770544,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01085591-3,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,intervention:Specific,0.00556010958072,0.140716379051,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01597505-1,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,intervention:Specific,0.00353374577572,0.71978104293,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,acute,16,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",Negative Control,superior,superior,,Y,True,NCT01598311-1,acute,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,intervention:Specific,0.00606723215335,0.140716379051,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,33,25,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01085591-7,sustained,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,intervention:Specific,0.0116514657639,0.0381318636151,equivalent
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,33,25,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01085591-10,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,intervention:Specific,0.0929989000021,0.000840759867245,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,33,25,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01597505-3,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,intervention:Specific,0.000313480225646,0.328978193057,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,33,25,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,20,100,10,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01598311-3,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,intervention:Specific,0.000829381132517,0.182089015367,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,32,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01085591-7,sustained,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,intervention:Specific,0.598330414011,2.38163914302E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,32,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01085591-10,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,intervention:Specific,0.91128485705,7.24580710852E-08,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,32,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01597505-3,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,intervention:Specific,0.204344951381,0.00051028163164,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,32,16,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,4,20,2,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01598311-3,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,intervention:Specific,0.259725455736,0.000123038284176,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01085591-7,sustained,250,2500,125,mg,BID,10,,antibiotic,"CB-183,315",yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,intervention:Specific,0.0224029280966,0.161450036173,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01085591-10,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,intervention:Specific,0.0852217470274,0.0115738131197,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01597505-3,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,intervention:Specific,0.00399482377283,0.598094303287,inconclusive
https://pubmed.ncbi.nlm.nih.gov/22802252,22802252,22802252.txt,True,2012,sustained,16,13,C. difficile disease,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,12,ATCC 43596,20,,spores,20,50,250,25,mg/kg,BID,5,,"CB-183,315",vancomycin,inferior,inferior,,Y,True,NCT01598311-3,sustained,500,5000,250,mg,BID,10,,antibiotic,"CB-183,315",no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,intervention:Specific,0.00674323652379,0.50098090438,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vehicle control,superior,superior,,Y,True,NCT01085591-1,acute,250,2500,125,mg,BID,10,,antibiotic,surotomycin,yes,66,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,61,intervention:Specific,0.0594829803476,0.0131819037876,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vehicle control,superior,superior,,Y,True,NCT01085591-3,acute,500,5000,250,mg,BID,10,,antibiotic,surotomycin,yes,67,therapeutic,Number of Participants With a Clinical Response Outcome of Clostridium Difficile Infection Cure at the End of Study Treatment,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,58,intervention:Specific,0.0431701892137,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vehicle control,superior,superior,,Y,True,NCT01597505-1,acute,500,5000,250,mg,BID,10,,antibiotic,surotomycin,no,290,therapeutic,Adjusted Percentage of Participants With a Clinical Outcome of Cure at the End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,"The 95% confidence interval (CI) were stratified Wilson intervals for the treatment group percentages and a stratified Newcombe interval for the treatment difference, constructed using the MRc stratum weights.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,229,intervention:Specific,0.0309060047382,0.733128473459,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,acute,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vehicle control,superior,superior,,Y,True,NCT01598311-1,acute,500,5000,250,mg,BID,10,,antibiotic,surotomycin,no,285,therapeutic,Adjusted Percentage of Participants Meeting Clinical Response Criteria for Cure at End of Treatment (EOT),positive,Percentage of participants,Non-Inferiority,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,Non-inferiority was declared when the lower bound of the 95% CI for the difference in adjusted percentage of cured subjects was > -10%.,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,237,intervention:Specific,0.0433546288232,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vancomycin 0.5 mg/kg,superior,superior,,Y,True,NCT01085591-7,sustained,250,2500,125,mg,BID,10,,antibiotic,surotomycin,yes,61,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,44,intervention:Specific,0.0122181165975,0.950377331117,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vancomycin 0.5 mg/kg,superior,superior,,Y,True,NCT01085591-10,sustained,500,5000,250,mg,BID,10,,antibiotic,surotomycin,yes,58,therapeutic,Number of Participants With a Recurrence of Clostridium Difficile Infection Through the 4-week Follow-up Period,positive,participants,,1,x,NCT01085591,"Study of CB-183,315 in Participants With Clostridium Difficile Infection",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01085591,48,intervention:Specific,0.0303715141412,0.503287120239,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vancomycin 0.5 mg/kg,superior,superior,,Y,True,NCT01597505-3,sustained,500,5000,250,mg,BID,10,,antibiotic,surotomycin,no,290,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at the End of Study,positive,Percentage of participants,not superior,"The 95% CI was stratified Wilson intervals for group percentages and a stratified Newcombe interval for the difference, using the MRc stratum weights. Stratified by age group and number of CDAD episodes.",x,NCT01597505,"Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-005)",All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01597505,175,intervention:Specific,0.00647491616228,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25993059,25993059,25993059.txt,True,2015,sustained,8,8,Clostridium difficile,positive,,Golden Syrian,M,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,False,therapeutic,12,ATCC 43596,20,,spores,20,0.5,2.5,0.5,mg/kg,QD,5,,surotomycin,vancomycin 0.5 mg/kg,superior,superior,,Y,True,NCT01598311-3,sustained,500,5000,250,mg,BID,10,,antibiotic,surotomycin,no,285,therapeutic,Adjusted Percentage of Participants With Sustained Clinical Response at End of Study,positive,Percentage of participants,not superior,Superiority was declared if the lower bound of the 95% CI of the adjusted difference in sustained response was > 0.,x,NCT01598311,"A Study of CB-183,315 in Participants With Clostridium Difficile Associated Diarrhea (MK-4261-006)",All,"Adult, Older Adult","18 Years to 89 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01598311,180,intervention:Specific,0.00821033701841,0.999999999985,inconclusive
https://pubmed.ncbi.nlm.nih.gov/16966409,16966409,16966409.txt,True,2006,sustained,15,4,C. difficile disease,positive,,Golden Syrian,,,,75,70-80g,hamster,,clindamycin+challenge+vancomycin,,cumulative mortality,False,therapeutic,87,VPI 10463,140000,CFU,spores,140000,20,80,20,mg/kg,QD,4,,MDX1388,Negative Control,superior,superior,,Y,True,NCT01513239-1,sustained,10,10,10,mg/kg,QD,1,,antibody,MDX1388,no,390,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,332,intervention:Variation,1,1.0092715341E-17,inconclusive
https://pubmed.ncbi.nlm.nih.gov/16966409,16966409,16966409.txt,True,2006,sustained,15,4,C. difficile disease,positive,,Golden Syrian,,,,75,70-80g,hamster,,clindamycin+challenge+vancomycin,,cumulative mortality,False,therapeutic,87,VPI 10463,140000,CFU,spores,140000,20,80,20,mg/kg,QD,4,,MDX1388,Negative Control,superior,superior,,Y,True,NCT01241552-6,sustained,10,10,10,mg/kg,QD,1,,antibody,MDX1388,no,386,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,319,intervention:Variation,1,6.91928354647E-15,inconclusive
https://pubmed.ncbi.nlm.nih.gov/16966409,16966409,16966409.txt,True,2006,sustained,22,15,C. difficile disease,positive,,Golden Syrian,,,,75,70-80g,hamster,,clindamycin+challenge+vancomycin,,cumulative mortality,False,therapeutic,87,VPI 10463,140000,CFU,spores,140000,80,320,60 CDA1 + 20 MDX1388,mg/kg,QD,4,60 mg/kg QD CDA1 + 20 mg/kg QD MDX1388 for 4 days,CDA1 + MDX1388,Negative Control,superior,superior,,Y,True,NCT00350298-3,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,CDA1 + MDX1388,no,101,therapeutic,Number of Participants With Recurrence of Clostridium Difficile Associated Disease (CDAD) [ Time Frame: Day 0 to Day 84 ],positive,participants,,,x,NCT00350298,Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00350298,7,intervention:Specific,3.34019260755E-18,1,inconclusive
https://pubmed.ncbi.nlm.nih.gov/16966409,16966409,16966409.txt,True,2006,sustained,22,15,C. difficile disease,positive,,Golden Syrian,,,,75,70-80g,hamster,,clindamycin+challenge+vancomycin,,cumulative mortality,False,therapeutic,87,VPI 10463,140000,CFU,spores,140000,80,320,60 CDA1 + 20 MDX1388,mg/kg,QD,4,60 mg/kg QD CDA1 + 20 mg/kg QD MDX1388 for 4 days,CDA1 + MDX1388,Negative Control,superior,superior,,Y,True,NCT01513239-3,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,CDA1 + MDX1388,no,395,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,Superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient),x,NCT01513239,A Study of MK-6072 and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-002),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01513239,333,intervention:Variation,0.415672387006,1.67617249493E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/16966409,16966409,16966409.txt,True,2006,sustained,22,15,C. difficile disease,positive,,Golden Syrian,,,,75,70-80g,hamster,,clindamycin+challenge+vancomycin,,cumulative mortality,False,therapeutic,87,VPI 10463,140000,CFU,spores,140000,80,320,60 CDA1 + 20 MDX1388,mg/kg,QD,4,60 mg/kg QD CDA1 + 20 mg/kg QD MDX1388 for 4 days,CDA1 + MDX1388,Negative Control,superior,superior,,Y,True,NCT01241552-7,sustained,20,20,10 and 10,mg/kg,QD,1,,antibody,CDA1 + MDX1388,no,383,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,not superior,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,323,intervention:Variation,0.412556283184,2.0299765095E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/16966409,16966409,16966409.txt,True,2006,sustained,86,28,C. difficile disease,positive,,Golden Syrian,,,,75,70-80g,hamster,,clindamycin+challenge+vancomycin,,cumulative mortality,False,therapeutic,87,VPI 10463,140000,CFU,spores,140000,60,240,60,mg/kg,QD,4,,CDA1,Negative Control,superior,superior,,Y,True,NCT01241552-1,sustained,10,10,10,mg/kg,QD,1,,antibody,CDA1,no,232,therapeutic,Percentage of Participants With CDI Recurrence,positive,Percentage of participants,,One sided p-value based on the Miettinen and Nurminen method stratified by SOC therapy (metronidazole vs. vancomycin vs. fidaxomicin) and hospitalization status (inpatient vs. outpatient).,x,NCT01241552,"A Study of MK-3415, MK-6072, and MK-3415A in Participants Receiving Antibiotic Therapy for Clostridium Difficile Infection (MK-3415A-001)",All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT01241552,172,intervention:Variation,0.999999177668,3.09083948356E-24,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,25,125,12.5,mg/kg,BID,5,,SMT19969,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.00790636910971,0.715850608855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.00790636910971,0.715850608855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,25,125,12.5,mg/kg,BID,5,,SMT19969,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.00790636910971,0.715850608855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,acute,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.00790636910971,0.715850608855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,25,125,12.5,mg/kg,BID,5,,SMT19969,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.0196915590125,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,25,125,12.5,mg/kg,BID,5,,SMT19969,SMT19969 25 mg/kg BID,superior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.000202049337748,0.997602220222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,8,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.215750850643,0.0223662426315,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,8,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,12,630,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.0110303242571,0.713929003685,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,25,125,12.5,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.107360761382,0.107360761382,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,9,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,25,125,12.5,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.00199559118965,0.879120833897,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.0196915590125,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25652749,25652749,25652749.txt,True,2015,sustained,10,10,Clostridium difficile infection,positive,SPF,Golden Syrian,,,,,,hamster,,clindamycin+challenge,clindamycin+challenge,cumulative mortality,True,therapeutic,27,BI1,225,,spores,~100-350,50,250,25,mg/kg,BID,5,,SMT19969,vehicle control,superior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.000202049337748,0.997602220222,inconclusive
https://pubmed.ncbi.nlm.nih.gov/18195066,18195066,18195066.txt,True,2008,acute,20,18,C. difficile disease,positive,,Golden Syrian,,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,100,500,100,mg/kg,QD,5,,rifaximin,Negative Control,inferior,,,Y,True,NCT00269399-1,acute,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,117,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,67,intervention:Specific,5.11320570027E-05,0.979201013799,inconclusive
https://pubmed.ncbi.nlm.nih.gov/18195066,18195066,18195066.txt,True,2008,acute,20,9,C. difficile disease,positive,,Golden Syrian,,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,25,125,25,mg/kg,QD,5,,rifaximin,Negative Control,inferior,,,Y,True,NCT00269399-1,acute,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,117,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,67,intervention:Specific,0.276655947233,0.0046284436819,inconclusive
https://pubmed.ncbi.nlm.nih.gov/18195066,18195066,18195066.txt,True,2008,acute,20,13,C. difficile disease,positive,,Golden Syrian,,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,rifaximin,Negative Control,inferior,,,Y,True,NCT00269399-1,acute,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,117,therapeutic,"Proportion of Participants Achieving Clinical Success, Where Clinical Success is Defined as Resolution or Improvement of Baseline Signs and Symptoms i.e., Abdominal Pain, Fever, Diarrhea. [ Time Frame: 14 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,67,intervention:Specific,0.0166905983344,0.144555450706,inconclusive
https://pubmed.ncbi.nlm.nih.gov/18195066,18195066,18195066.txt,True,2008,sustained,8,8,C. difficile disease,positive,,Golden Syrian,,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,100,500,100,mg/kg,QD,5,,rifaximin,Negative Control,inferior,,,Y,True,NCT00269399-3,sustained,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,67,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,61,intervention:Specific,0.0548131519655,0.0281364234195,inconclusive
https://pubmed.ncbi.nlm.nih.gov/18195066,18195066,18195066.txt,True,2008,sustained,1,1,C. difficile disease,positive,,Golden Syrian,,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,25,125,25,mg/kg,QD,5,,rifaximin,Negative Control,inferior,,,Y,True,NCT00269399-3,sustained,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,67,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,61,intervention:Specific,0.61915684511,0.0850916797581,inconclusive
https://pubmed.ncbi.nlm.nih.gov/18195066,18195066,18195066.txt,True,2008,sustained,3,3,C. difficile disease,positive,,Golden Syrian,,,,,,hamster,,clindamycin+challenge,,cumulative mortality,True,therapeutic,87,VPI 10463,100000,CFU,,10^5,50,250,50,mg/kg,QD,5,,rifaximin,Negative Control,inferior,,,Y,True,NCT00269399-3,sustained,1200,12000,400,mg,TID,10,400 mg TID,antibiotic,rifaximin,no,67,therapeutic,"Proportion of Participants Recurrence-free of Clostridium Difficile-associated Diarrhea (CDAD), After Achieving Clinical Success [ Time Frame: 42 days ]",positive,participants,,,x,NCT00269399,A Trial to Compare Xifaxan to Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT00269399,61,intervention:Specific,0.265829600859,0.0439898358147,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0506409827577,0.0985623466632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0361944276912,0.221376591861,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,2.95203598804E-05,0.999999894764,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.0222479008465,0.796895739491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0196118470907,0.61666733265,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0487091701276,0.274849562678,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00302832237273,0.966652559342,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00832241309005,0.870148336457,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.0223735387666,0.648139592661,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0609151469155,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0270796536661,0.796895739491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.784434731355,0.000793879152776,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.737259519872,0.000816855515559,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.0308705224306,0.737259519872,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.618824247689,0.0110276285896,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.737259519872,0.0222655449982,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.794552451454,0.0104408275571,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.327659521372,0.327659521372,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.459996170371,0.115691431694,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.737259519872,0.0400692944109,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.798225439365,0.00314037255453,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.644583057473,0.00640873833916,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0506409827577,0.0985623466632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0361944276912,0.221376591861,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,2.95203598804E-05,0.999999894764,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.0222479008465,0.796895739491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0196118470907,0.61666733265,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0487091701276,0.274849562678,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00302832237273,0.966652559342,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00832241309005,0.870148336457,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.0223735387666,0.648139592661,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0609151469155,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0270796536661,0.796895739491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.100762375551,0.100762377552,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0816692732814,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,0.000658093206647,0.999999894761,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.0570077474561,0.771518662632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0553548547682,0.616658708441,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.123325620755,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.0189870662628,0.966651914166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.0324980893798,0.870145249948,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.0515504999168,0.648139123829,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.143065328273,0.140726933807,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0671890987639,0.78165981581,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT01591863-1,acute,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Clinical Response. (day 10),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,34,intervention:Specific,0.0506409827577,0.0985623466632,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02179658-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Clinical cure at end of treatment,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,87,intervention:Specific,0.0361944276912,0.221376591861,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02743234-3,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,Number of patients with global resolution (clinical resolution AND negative Clostridium difficile PCR test) 8 weeks after primary treatment [ Time Frame: 8 weeks ],positive,participants,,chi^2 and Kruskal-Wallis anova,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,8,intervention:Specific,2.95203598804E-05,0.999999894764,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02218372-1,acute,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,98,therapeutic,Percentage of Participants With Confirmed Clinical Response (CCR) at End of Treatment (EOT) +2 Days,positive,Percentage of participants,,Adjusted difference of CCR at EOT + 2 Days. Adjusted treatment difference of proportions was calculated using a stratified Cochran-Mantel-Haenszel (CMH) method. Newcombe 95% confidence intervals (CIs) presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,76,intervention:Specific,0.0222479008465,0.796895739491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02437591-1,acute,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,25,therapeutic,CDI clinical response [ Time Frame: Day 12 ],positive,participants,,,https://astellasclinicalstudyresults.com/study.aspx?ID=227,NCT02437591,Study to Evaluate the Pharmacokinetics of Fidaxomicin in Inflammatory Bowel Disease (IBD) Subjects With Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02437591,20,intervention:Specific,0.0196118470907,0.61666733265,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT01818141-1,acute,400,4000,200,mg,BID,10,200 mg BID for 10 days,antibiotic,Tiacumicins B,no,12,therapeutic,C. Difficile Spore Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,11,intervention:Specific,0.0487091701276,0.274849562678,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT01818141-3,acute,400,4000,200,mg,BID,10,200mg BID for 10 days,antibiotic,Tiacumicins B,no,7,therapeutic,C. Difficile Vegetative Cell Reduction of at Least 2 Log 10 Colony Forming Units (CFU)/g of Stool,positive,participants,,,x,NCT01818141,Study to Assess Inhibition of Spore Production in Patients With C. Difficile Infections: Fidaxomicin Versus Vancomycin,All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT01818141,4,intervention:Specific,0.00302832237273,0.966652559342,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT00097422-1,acute,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,14,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,10,intervention:Specific,0.00832241309005,0.870148336457,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT00097422-3,acute,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.0223735387666,0.648139592661,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT00097422-5,acute,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,16,therapeutic,Relief of symptoms of CDAD,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,15,intervention:Specific,0.0609151469155,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,acute,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02254967-1,acute,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,clinical reponse 2 days after end of treatment,positive,participants,,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,138,intervention:Variation,0.0270796536661,0.796895739491,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.00624233911604,0.987962077732,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.0091722520458,0.99923188908,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.00101771878066,0.999021651583,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.000475398206851,0.998754045854,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.0689725771475,0.00700733079748,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.0532141467162,0.375779441012,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.167755383518,0.0687091701003,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.0577568940776,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,0.2,1,0.2,mg/kg,QD,5,,Tiacumicins B,control,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.0147510485116,0.999406667216,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.340331420789,0.125959925946,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.369484592801,0.0834840435835,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.327659520512,0.327659520512,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.129178600098,0.501635291352,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.960278358772,3.46754916418E-06,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.740007394987,0.0247367232635,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.980591037083,0.00220562337053,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.835748653071,0.00427953734511,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,3,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.457666167285,0.0566259303081,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.00624233911604,0.987962077732,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.0091722520458,0.99923188908,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.00101771878066,0.999021651583,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.000475398206851,0.998754045854,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.0689725771475,0.00700733079748,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.0532141467162,0.375779441012,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.167755383518,0.0687091701003,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.0577568940776,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,1,5,1,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.0147510485116,0.999406667216,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.0220620654942,0.987961717228,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.0313045826314,0.999231866037,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.00910003508777,0.9990216223,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.00459033750549,0.998754009707,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.149653286296,0.0104284340651,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.114150415211,0.37579453956,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.327659520512,0.06871947662,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.140017298622,0.167114223334,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,5,5,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,,2926,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,vancomycin,superior,superior,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.0390167147613,0.999406649416,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT01591863-2,sustained,400,4000,200,mg,BID,10,"different dosages by age, only recorded 6 year and older dosage",antibiotic,Tiacumicins B,no,38,therapeutic,Evaluate the Clinical Outcome by Assessment of Sustained Clinical Response. (day 28),positive,Percentage of participants,,,x,NCT01591863,"Safety, Tolerability, and Pharmacokinetics of Fidaxomicin in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD)",All,"Child, Adult","6 Months to 18 Years Â (Child, Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT01591863,25,intervention:Specific,0.00624233911604,0.987962077732,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02179658-3,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,104,therapeutic,Global cure at end of treatment,positive,participants,not non-inferior,with a treatment difference of 1.2% (95% CI11.3e13.7).The lower limit of the 95% CI for this difference was not above thenon-inferiority margin of10%,https://pubmed.ncbi.nlm.nih.gov/29934056/,NCT02179658,A Study to Compare Safety and Efficacy of OPT-80(Fidaxomicin) With Vancomycin in Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,"Adult, Older Adult","20 Years and older Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02179658,70,intervention:Specific,0.0091722520458,0.99923188908,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02743234-9,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,24,therapeutic,"initially cured, then relapsed",positive,participants,,,https://doi.org/10.1053/j.gastro.2018.12.019,NCT02743234,Fecal Microbiota Transplantation for Relapsing Clostridium Difficile Infection,All,"Adult, Older Adult","18 Years to 99 Years Â (Adult, Older Adult)",Phase 3,https://ClinicalTrials.gov/show/NCT02743234,13,intervention:Specific,0.00101771878066,0.999021651583,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02784002-1,sustained,400,4000,200,mg,BID,10,,antibiotic,Tiacumicins B,no,13,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,6,intervention:Specific,0.000475398206851,0.998754045854,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02218372-3,sustained,400,4000,200,mg,BID,10,"staggered age dependent dose, recorded >6 years dosage",antibiotic,Tiacumicins B,no,76,therapeutic,Percentage of Participants With Sustained Clinical Response (SCR) at EOT +9 Days,positive,Percentage of participants,,Adjusted difference of SCR at EOT +9 days. Adjusted treatment difference of proportions was calculated using a stratified CMH method. Newcombe 95% CIs presented for adjusted treatment difference.,x,NCT02218372,A Study to Investigate the Safety and Efficacy of Fidaxomicin (Oral Suspension or Tablets) and Vancomycin (Oral Liquid or Capsules) in Pediatric Subjects With Clostridium Difficile-associated Diarrhea (CDAD),All,Child,up to 17 Years Â (Child),Phase 3,https://ClinicalTrials.gov/show/NCT02218372,71,intervention:Specific,0.0689725771475,0.00700733079748,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT00097422-7,sustained,100,1000,50,mg,BID,10,50 mg,antibiotic,Tiacumicins B,yes,10,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,9,intervention:Specific,0.0532141467162,0.375779441012,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT00097422-9,sustained,200,2000,100,mg,BID,10,100 mg,antibiotic,Tiacumicins B,yes,12,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,12,intervention:Specific,0.167755383518,0.0687091701003,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT00097422-11,sustained,400,4000,200,mg,BID,10,200 mg,antibiotic,Tiacumicins B,yes,15,therapeutic,Recurrence Rate.,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/18955525/,NCT00097422,OPT-80 in Clostridium Difficile-Associated Diarrhea (CDAD),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT00097422,14,intervention:Specific,0.0577568940776,0.167755383518,inconclusive
https://pubmed.ncbi.nlm.nih.gov/1929250,1929250,1929250.txt,True,1991,sustained,8,8,C. difficile disease,positive,,Golden Syrian,M,,,90,80-100g,hamster,,clindamycin+challenge,oral,cumulative mortality,True,therapeutic,1,ATCC9689,1000000,,,10^6,5,25,5,mg/kg,QD,5,,Tiacumicins B,Tiacumicins C,equivalent,equivalent,,Y,True,NCT02254967-3,sustained,400,5600,200,mg,BID,5,1 day gap + 200 mg QD for 18 days,antibiotic,Tiacumicins B,no,177,therapeutic,sustained clinical cure 30 days after end of treatment,positive,participants,Superiority,Cochran-Mantel-Haenszel,https://doi.org/10.1016/s1473-3099(17)30751-x,NCT02254967,A Phase IIIB/IV Study to Compare the Efficacy of Vancomycin Therapy to Extended Duration of Fidaxomicin Therapy in the Clinical Cure of Clostridium Difficile Infection (CDI) in an Older Population,All,"Adult, Older Adult","60 Years and older Â (Adult, Older Adult)",Phase 4,https://ClinicalTrials.gov/show/NCT02254967,124,intervention:Variation,0.0147510485116,0.999406667216,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,acute,10,10,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,10,50,10,mg/kg,QD,5,,SMT19969,vancomycin,equivalent,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.00790636910971,0.715850608855,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,20,100,20,mg/kg,QD,5,,SMT19969,Negative Control,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.000333990718224,0.715863059935,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,acute,20,20,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,50,250,50,mg/kg,QD,5,,SMT19969,Negative Control,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.000333990718224,0.715863059935,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,acute,10,9,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,10,50,10,mg/kg,QD,5,,SMT19969,Negative Control,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.0345414138825,0.375779440166,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,acute,20,19,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,20,100,20,mg/kg,QD,5,,SMT19969,Negative Control,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.00139961491684,0.411405236911,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,acute,20,19,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,50,250,50,mg/kg,QD,5,,SMT19969,Negative Control,superior,superior,,Y,True,NCT02092935-1,acute,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,36,therapeutic,Clinical response at test of cure,positive,participants,,,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,28,intervention:Specific,0.00139961491684,0.411405236911,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,10,50,10,mg/kg,QD,5,,SMT19969,Negative Control,superior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,1,1.71121350155E-09,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,10,0,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,10,50,10,mg/kg,QD,5,,SMT19969,Negative Control,superior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.997602220222,0.000202049337748,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,11,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,20,100,20,mg/kg,QD,5,,SMT19969,"SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole]",equivalent,inferior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.818222120179,7.33903902633E-05,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,11,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,20,100,20,mg/kg,QD,5,,SMT19969,"SMT19969 [2,2'-bis(4-pyridyl)3H,3'-H 5,5-bibenzimidazole]",equivalent,inferior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.0894464107944,0.235896602565,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,14,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,50,250,50,mg/kg,QD,5,,SMT19969,vancomycin,equivalent,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.424836745993,0.00195124133941,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,14,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,challenge+clindamycin,cumulative mortality,True,therapeutic,27,VA5,894206,CFU,,5.11 to 6.22 log10,50,250,50,mg/kg,QD,5,,SMT19969,vancomycin,equivalent,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.0107192863155,0.517527768509,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,10,50,10,mg/kg,QD,5,,SMT19969,vancomycin,inferior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.215750850643,0.0223662426315,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,10,8,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,10,50,10,mg/kg,QD,5,,SMT19969,vancomycin,inferior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,0.0110303242571,0.713929003685,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,18,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,20,100,20,mg/kg,QD,5,,SMT19969,vancomycin,inferior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.0202054183644,0.0691616057051,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,18,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,20,100,20,mg/kg,QD,5,,SMT19969,vancomycin,inferior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,7.48206919715E-05,0.913300168137,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,19,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,50,250,50,mg/kg,QD,5,,SMT19969,vancomycin,inferior,superior,,Y,True,NCT02092935-3,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,28,therapeutic,Sustained clinical response,positive,participants,superior,wald,https://pubmed.ncbi.nlm.nih.gov/28461207/,NCT02092935,A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD),All,"Adult, Older Adult","18 Years to 90 Years Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02092935,24,intervention:Specific,0.00719066212949,0.160182670913,inconclusive
https://pubmed.ncbi.nlm.nih.gov/25022586,25022586,25022586.txt,True,2014,sustained,20,19,C. difficile disease,positive,,Golden Syrian,M,,,100,80-120g,hamster,,challenge+clindamycin,,cumulative mortality,True,therapeutic,428,VA11,752846,CFU,,5.44 to 6.09 log10,50,250,50,mg/kg,QD,5,,SMT19969,vancomycin,inferior,superior,,Y,True,NCT02784002-2,sustained,400,4000,200,mg,BID,10,,antibiotic,SMT19969,no,14,therapeutic,Measure sustained clinical response (SCR) rates [ Time Frame: 40 days ],positive,participants,equivalence,"estimated treatment difference  2.9%  (95%  CI  −30.8,  36.7",https://academic.oup.com/ofid/article/4/suppl_1/S526/4295841,NCT02784002,A Study of Ridinilazole (SMT19969) Compared With Fidaxomicin for the Treatment of Clostridium Difficile Infection (CDI),All,"Adult, Older Adult","18 Years and older Â (Adult, Older Adult)",Phase 2,https://ClinicalTrials.gov/show/NCT02784002,7,intervention:Specific,1.22622077129E-05,0.990016208033,inconclusive
